



10588323- GAU: 1644  
11/1644

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application No. 10/588,323

Confirmation No. 2783

Applicant: MAGILAVY

Filing Date: February 7, 2005

TC/AU: 1644

Examiner: Unassigned

Docket No.: 253780

Customer No.: 23460

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner initial the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

Applicants also bring to the Examiner's attention the following U. S. applications, which are commonly assigned in whole or in part to Astellas US LLC and which relate to subject matter similar to that claimed in the present application. The present application claims priority to

Application No. 10/588,323

Information Disclosure Statement

one or more of the listed applications. Copies of the file wrappers of each application will be filed in a supplemental Information Disclosure Statement at a later date.



U.S. APPLICATIONS		STATUS		
U.S. APPLICATIONS	U.S. FILING DATE	PATENT No., if Issued	PENDING	ABANDONED/ EXPIRED
1. 60/098,456	08/31/1998			X
2. 09/796,033	02/27/2001			X
3. PCT/US99/20026	08/31/1999			X
4. 11/398,908	04/06/2006		X	
5. 60/307,688	07/24/2001			X
6. 60/382,459	05/22/2002			X
7. 10/484,329	07/10/2002		X	
8. PCT/US02/21631	07/10/2002			X
9. 60/568,371	05/04/2004			X
10. PCT/US05/15531	05/04/2005			X
11. 11/578,342	05/04/2005		X	
12. 60/542,311	02/06/2004			X
13. PCT/US05/03907	02/06/2005			X
14. 60/568,955	05/07/2004			X
15. PCT/US05/16265	05/09/2005			X
16. 11/578,391	05/09/2005			
17. 07/667,971	03/12/1991			X
18. 07/770,967	10/07/1991			X
19. PCT/US92/02050	03/12/1992			X
20. 07/940,861	10/21/1992	5,547,853		
21. 08/459,512	06/02/1995	5,728,677		
22. 08/459,657	06/02/1995	5,914,111		
23. 08/460,132	06/02/1995	5,928,643		
24. 07/772,705	10/07/1991			X
25. 07/850,706	03/12/1992			X
26. PCT/US92/08754	10/06/1992			X
27. 08/211,631	04/05/1994			X
28. 08/459,350	06/02/1995			X
29. 07/770,969	10/07/1991			X
30. 07/862,022	04/02/1992			X
31. PCT/US92/08755	10/06/1992			X
32. 08/466,465	06/06/1995	6,162,432		
33. 09/730,465	12/05/2000	6,764,681		
34. 10/778,373	02/13/2004		X	
35. 11/282,853	11/18/2005		X	
36. 60/265,964	02/01/2001			X
37. PCT/US02/02314	08/08/2002			X
38. 10/470,764	01/25/2002			X
39. 10/329,599	12/26/2002			X

/Phillip Gambel/

09/30/2008

Application No. 10/588,323

## Information Disclosure Statement

U.S. APPLICATIONS		STATUS		
U.S. APPLICATIONS	U.S. FILING DATE	PATENT No., if Issued	PENDING	ABANDONED/ EXPIRED
40. 11/312,627	12/20/2005		X	
41. 07/057,615	06/03/1987	4,956,281		
42. PCT/US88/01924	06/03/1988			X
43. 07/365,107	03/20/1989			X
44. 07/537,031	03/20/1989			X
45. 08/381,299	01/31/1995			X
46. 07/237,309	08/26/1988	5,185,441		
47. PCT/89/03652	08/24/1989			X
48. 07/959,550	10/13/1992	5,354,665		
49. 08/261,463	06/17/1994			X
50. 08/460,243	06/02/1995			X
51. 60/623,364	10/28/2004			X
52. PCT/US05/39070	10/28/2005			X

/Phillip Gambel/

09/30/2008

The Information Disclosure Statement is being filed:

☒ **within** any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

☐ **after** (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes *one* of:

☐ the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).

- or -

☐ the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).

☐ **after** the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).

☐ **after** the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and **within** thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper

Application No. 10/588,323

Information Disclosure Statement

containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.

**Copies of the References**

- ☐ Copies of all of the references listed on the enclosed Form 1449 are enclosed herewith.
- ☒ Copies of U.S. patents and patent applications that are listed on the accompanying Form 1449 are not enclosed herewith. Copies of other references identified on the accompanying Form 1449 are enclosed herewith.
- ☒ For each reference not in the English language, attached is an English translation, a concise explanation of relevance, an English-language equivalent/patent, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office pursuant to 37 CFR 1.98(a)(3).
- ☒ A copy of the foreign search report is enclosed herewith.
- ☐ The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPLICATIONS		STATUS ( <i>check one</i> )		
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
1.				
2.				
3.				

**Statement under 37 CFR 1.97(e)**

- ☐ The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- ☐ The **undersigned** hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the

Application No. 10/588,323

Information Disclosure Statement

Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

**Statement under 37 CFR 1.704(d)**

- ☐ The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

**Fees**


- ☒ **No fee** is owed by the applicant(s).  
☐ Charge Deposit Account No. 12-1216 in the amount of **\$180.00** (37 CFR 1.17(p)). (A duplicate copy of this communication is enclosed for that purpose, unless submitted via EFS-Web.)

**Authorization to Charge Additional Fees**

- ☒ If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose, unless submitted via EFS-Web.)

**Instructions as to Overpayment**


- ☒ Credit Account No. 12-1216.  
☐ Refund

  
Christine M. Cochran, Reg. No. 52,757  
LEYDIG, VOIT & MAYER, LTD.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-6731  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)


Date: August 31, 2007

Application No. 10/588,323

Information Disclosure Statement

<b>MAILING/TRANSMISSION CERTIFICATE UNDER 37 CFR 1.8 OR 1.10</b>			
I hereby certify that this document and all accompanying documents are, on the date indicated below, being <input type="checkbox"/> deposited with the U.S. Postal Service using "Express Mail" service in an envelope addressed in the same manner indicated on this document with Express Mail Label Number <input checked="" type="checkbox"/> deposited with the U.S. Postal Service with sufficient postage as first class mail in boxes addressed in the same manner indicated on this document, or <input type="checkbox"/> facsimile transmitted to the U.S. Patent and Trademark Office at fax number: (571) 273-8300.			
<i>Name (Print/Type)</i>	Jeannie Rapstad		
<i>Signature</i>		<i>Date</i>	August 31, 2007

Please type a plus sign (+) inside this box →



10588323 - GAU: 1644

Substitute for form 1449A/B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

33

## **Complete if Known**

Application Number	10/588,323
Filing Date	February 7, 2005
First Named Inventor	MAGILAVY
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	253780

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	A1	2003/0044406	A1	Dingivan	03/06/2003	
	A2	2003/0185824	A1	Vaishnow et al.	10/02/2003	
	A3	2002/0009446	A1	Magilavy	01/24/2002	
	A4	4,579,844		Rovee et al.	04/01/1986	
	A5	4,681,760		Fathman	07/21/1987	
	A6	4,738,297		Taniguchi et al.	04/19/1988	
	A7	4,738,927		Taniguchi et al.	04/19/1988	
	A8	4,816,397		Boss et al.	03/28/1989	
	A9	4,816,567		Cabilly et al.	03/28/1989	
	A10	4,833,092		Geysen	05/23/1989	
	A11	4,956,281		Wallner et al.	09/11/1990	
	A12	5,047,336		Cate et al.	09/10/1991	
	A13	5,116,964		Capon et al.	05/26/1992	
	A14	5,122,514		Boger et al.	06/16/1992	
	A15	5,185,441		Wallner et al.	02/09/1993	
	A16	5,190,859		Dustin et al.	03/02/1993	
	A17	5,225,538		Capon et al.	07/06/1993	
	A18	5,336,603		Capon et al.	09/09/1994	
	A19	5,547,853		Wallner et al.	08/20/1996	
	A20	5,556,943		Yamashita et al.	09/17/1996	
	A21	5,565,335		Capon et al.	10/15/1996	
	A22	5,728,677		Wallner et al.	03/17/1998	
	A23	5,730,979		Bazin et al.	03/24/1998	
	A24	5,817,311		Bazin et al.	10/06/1998	
	A25	5,914,111		Wallner et al.	06/22/1999	
	A26	5,928,643		Wallner et al.	07/27/1999	
	A27	5,951,983		Bazin et al.	09/14/1999	
	A28	5,952,499		Whittaker et al.	09/14/1999	
	A29	6,117,655		Capon et al.	09/12/2000	
	A30	6,162,432		Wallner et al.	12/19/2000	
	A31	6,270,766		Feldman et al.	08/07/2001	
	A32	6,337,337	B1	Buck	01/08/2002	
	A33	6,384,198	B1	Diegel et al.	05/07/2002	
	A34	6,764,681	B2	Wallner et al.	07/20/2004	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No* +
	B1	CA	1,326,940		Dana-Farber Cancer Institute, Inc.	Feb. 08, 1994		
Examiner Signature		/Phillip Gambel/			Date Considered	09/30/2008		

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

/Phillip Gambel/

09/30/2008

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 33

**Complete if Known**

Application Number	10/588,323
Filing Date	February 7, 2005
First Named Inventor	MAGILAVY
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	253780

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No* +
	B2	CA	1,338,078		Michael, Jacob Gabriel	Feb. 20, 1996		
	B3	CA	2,120,500		The General Hospital Corporation	Apr. 15, 1993		
	B4	EP	0 200 412	A2	The Board of Trustees of the Leland Stanford Junior University	Dec. 10, 1986		
	B5	EP	0 260 880	A2	Dana-Farber Cancer Institute, Inc.	Mar. 23, 1988		
	B6	EP	0 280 578	A2	Dana Farber Cancer Institute	Aug. 31, 1988		
	B7	EP	0 314 317	B1	Genentech, Inc.	Mar. 5, 1989		
	B8	EP	0 325 262	B1	The General Hospital Corporation	Mar. 16, 1994		
	B9	EP	0 325 266	A2	ESPE Stiftung & Co.Produktions- und Vertriebs KG	Jul. 26, 1989		X+
	B10	EP	0 345 466	A2	Eastman Kodak Company	Dec. 13, 1989		
	B11	EP	0 368 684	B2	Medical Research Council	May. 16, 1990		
	B12	EP	0 503 646	A1	Biogen, Inc.	Sep. 16, 1992		
	B13	EP	0 503 648	A1	Biogen, Inc.	Sep. 16, 1992		
	B14	EP	0 517 174	B1	Kanegafuchi Kagaku Kogyo Kabushiki Kaisha	Dec. 9, 1992		
	B15	EP	0 607 332	B1	Biogen, Inc.	Dec. 17, 1997		
	B16	EP	0 626 447	A1	Bristol-Myers Squibb Company	Nov. 30, 1994		
	B17	EP	1 637 155	A1	Biogen Idec MA Inc.	Mar. 22, 2006		
	B18	JP	1-502875	T2	Medical Research Council	Oct. 24, 1990		
	B19	JP	2-503269	T2	The Trustees of Columbia University in the City of New York Smithkline Beckman Corporation	Oct. 11, 1990		
	B20	JP	7-502495	T2	Biogen, Inc.	Mar. 16, 1995		X+
	B21	JP	2-501113	T2	Dana-Farber Cancer Institute, Inc.	Apr. 19, 1990		X+
	B22	JP	63-233917	T2	Cosmo Kaihatsu KK	Sep. 29, 1988		
	B23	WO	88/06592	A1	Dana Farber Cancer Institute	Sep. 7, 1988		
	B24	WO	88/07089	A1	Medical Research Council	Sep. 22, 1988		
	B25	WO	88/09820	A1	Biogen N.V. et al.	Dec. 15, 1988		
	B26	WO	89/02922	A1	Genentech, Inc.	Apr. 6, 1989		
	B27	WO	89/07452	A1	Medical Research Council	Aug. 24, 1989		
	B28	WO	90/02181	A1	Biogen, Inc.	Mar. 8, 1990		
	B29	WO	90/07517	A1	The Salk Institute for Biological Studies	Jul. 12, 1990		
	B30	WO	90/08187	A1	Dana Farber Cancer Institute	July 26, 1990		
	B31	WO	90/09195	A1	Celltech Limited	Aug. 23, 1990		
	B32	WO	90/12099	A1	Biogen, Inc.	Oct. 18, 1990		
	B33	WO	91/07987	A1	Immunomedics, Inc.	Jun. 13, 1991		
	B34	WO	91/10741	A1	Cell Genesys, Inc.	Jul. 25, 1991		

Examiner Signature

/Phillip Gambel/

Date Considered

09/30/2008

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./



Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 33

**Complete if Known**

Application Number	10/588,323
Filing Date	February 7, 2005
First Named Inventor	MAGILAVY
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	253780

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No* +
	B35	WO	91/11461	A1	Biogen, Inc.	Aug. 8, 1991		
	B36	WO	91/11194	A1	Biogen, Inc.	Aug. 8, 1991		
	B37	WO	92/07581	A1	Autoimmune, Inc.	May 14, 1992		
	B38	WO	93/06866	A2	Biogen, Inc.	Apr. 15, 1993		
	B39	WO	93/06852	A2	Biogen, Inc.	Apr. 15, 1993		
	B40	WO	95/24217	A1	Dana-Farber Cancer Institute	Sep. 14, 1995		
	B41	WO	98/05357	A1	The Kennedy Institute of Rheumatology	Feb. 12, 1998		
	B42	WO	2002/060480	A1	Biogen, Inc.	Aug. 8, 2002		
	B43	WO	03/009740	A3	Biogen, Inc.	Feb. 6, 2003		

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C1	ABRAHAM et al. (1990) "Interactions between lymphocytes and dermal fibroblasts: An <i>in vitro</i> model of cutaneous lymphocyte trafficking," Experimental Cell Research 190, 118-126		
	C2	ABRAHAM, et al., (1991) "Expression and Function of Surface Antigens on Scleroderma Fibroblasts" Arthritis and Rheumatism 34(9):1164-1172.		
	C3	ACTIS, et al., "Continuously Infused Cyclosporine at Low Dose Is Sufficient to Avoid Emergency Colectomy in Acute Attacks of Ulcerative Colitis Without the Need for High-Dose Steroids", Journal of Clinical Gastroenterology, vol. 17, No. 1, pp. 10-13, 1993.		
	C4	ADAMS, "How the Immune System Works and Why it Causes Autoimmune Diseases" Immunology Today, 1996 Jul.; 17(7):300-2.		
	C5	ALBERT-WOLF, et al., "Immunomodulatory Properties of Soluble Recombinant Human CD58 (LFA-3) Molecules", Dev. Biol. Standard 77:87-92 (1992)		
	C6	ALBERTS et al., Molecular Biology of the Cell, 1994, Garland Publishing, Inc., New York, NY, pp. 1243, 1994.		
	C7	ALCOVER, et al., "Interdependence of CD3-Ti and CD2 Activation Pathways in Human T Lymphocytes", The EMBO Journal, vol. 7, No. 7, pp. 1973-1977, 1988.		
	C8	ALORA, et al., "Narrow-band (311 nm) UVB Phototherapy: An Audit of the First Year's experience at the Massachusetts General Hospital", Photodermatology Photoimmunology & Photomedicine, vol. 13, pp. 82-84, 1997.		
	C9	ALTMAN et al. (1990) "Transfection of genes for cell surface products involved in antigen presentation-applications to the understanding of autoimmunity" Autoimmunity 7:213-220.		
	C10	ALTMAYER, et al. "Traitement Systemique Du Psoriasis Par Les Derives De L'Acide Fumarique", Ann. Dermatol. Venereol, vol. 123, pp. 838-841, 1996		
	C11	ALTSHULER, "Implications of Psoriasis as a New Disease", Dermatology, vol. 199, pp. 1-2, 1999.		
	C12	AMEEN, "Genetic basis of psoriasis vulgaris and its pharmacogenetic potential", Pharmacogenomics 4(3); 297-308 (2003)		

Examiner Signature

/Phillip Gambel/

Date Considered

09/30/2008

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Examiner Name	Unassigned				
Sheet	4	of	33	Attorney Docket Number	253780

## OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C13	ARBUCKLE, et al., "Psoriasis" Pediatrics in Review, 1998 Mar.; 19(3):106-7.		
	C14	ARELLANO, "Risk of Cancer with Cyclosporine in Psoriasis" International Journal of Dermatology, vol. 36, No. 1, pp. 15-17, 1997.		
	C15	AREND, "The Pathophysiology and Treatment of Rheumatoid Arthritis" Arthritis & Rheumatism, vol. 40, No. 4, pp. 595-597, 1997.		
	C16	ARMITAGE, "Tests for Linear Trends in Proportions and Frequencies" Biometrics, 11, 375-386, 1955.		
	C17	ARTHOS, et al., "Identification of the Residues in Human CD4 Critical for the Binding of HIV", Cell, 57(3):469-481 (1989)		
	C18	ASADULLAH, et al., "IL-10 Is a Key Cytokine in Psoriasis", Journal of Clinical Investigation, vol. 101, No. 4, pp. 783-794, 1998.		
	C19	ASHCROFT, et al., "Clinical Measures of Disease Severity and Outcome in Psoriasis: A Critical Appraisal of their Quality" British Journal of Dermatology, vol. 141, pp. 185-191, 1999.		
	C20	ATCC Cell Lines and Hybridomas 8th Edition 1994 p. 420 only.		
	C21	BAADSGAARD et al. (1989) "Psoriatic Epidermal Cells Demonstrate Increased Nos. and Function of Non-Langerhans Antigen-presenting Cells" J. Invest. Dermatol. 92:190-195.		
	C22	BANGHA et al., "Evaluation of Topical Antipsoriatic Treatment by Chromametry, Visiometry and 20-MHz Ultrasound in the Psoriasis Plaque Test", Skin Pharmacology, vol. 9, pp. 298-306, 1996.		
	C23	BANSIL, et al. "Multiple Sclerosis: Immune Mechanism and Update on Current Therapies" Annals of Neurology, 37 (S1): 87-101, 1995.		
	C24	BARBOSA et al. (1986) "Gene Mapping and Somatic Cell Hybrid Analysis Of The Role Of Human Lymphocyte Function-Associated Antigen-3 (LFA-3) in CTL-Target Cell Interactions" J. Immunol. 136 (8):3085-3091.		
	C25	BARDOLPH et al., "Psoriasis: A Review of Present and Future Management", Nursing Standard, vol. 12, No. 21, pp. 43-47, 1998.		
	C26	BARKER, "Psoriasis" Journal of the Royal College of Physicians of London, vol. 31, No. 3, pp. 238-240, 1997.		
	C27	BARKER, "The Pathophysiology of Psoriasis", The Lancet, vol. 338, pp. 227-230, 1991.		
	C28	BARKER, et al., "Leukocyte-Endothelium Interactions in Cutaneous Inflammatory Processes", Springer Seminars in Immunopathology, vol. 13, pp. 355-367, 1992.		
	C29	BARKER, et al., "Topical Maxacalcitol for the Treatment of Psoriasis Vulgaris: A Placebo-Controlled, Double-Blind, Dose-Finding Study with Active Comparator", British Journal of Dermatology, vol. 141, pp. 274-278, 1999.		
	C30	BARSOUM, "Introduction of Stable High-Copy-Number DNA into Chinese Hamster Ovary Cells by Electroporation" DNA and Cell Biology, vol. 9, No. 4, pp. 293-300, 1990.		
	C31	BARTHELS et al., "Isolation and Nucleotide Sequence of Mouse NCAM cDNA that Codes for a M.sub.r 79000 Polypeptide Without a Membrane-Spanning Region," EMBO Journal, 6 (4), pp. 907-914 (1987).		
	C32	BAY, et al., "Psoriasis Patients have T-cells with Reduced Responsiveness to Common Mycobacterial Antigens", FEMS Immunology and Medical Microbiology, vol. 21, pp. 65-70, 1998.		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 33

**Complete if Known**

Application Number	10/588,323
Filing Date	February 7, 2005
First Named Inventor	MAGILAVY
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C33	BELL, et al, "CD2 and the Regulation of T Cell Anergy", J Immunol. 1995 Sep. 15;155(6):2805-7.		
	C34	BENJAMIN, et al., "MAb to cell interaction antigens block human T-dependent B cell activation", J. Cell. Biochem. Keystone Symposia on Molecular & Cellular Biology Supp. 17B:172 (1993)		
	C35	BENNET, "Cyclosporine Nephrotoxicity: Implications for Dermatology", International Journal of Dermatology, vol. 36(Supp. 1), pp. 11-14, 1997.		
	C36	BENTON et al., "Screening the Recombinant Clones by Hybridization to Single Plaques in situ", Science, 196, 180-182 (1977).		
	C37	BERTH-JONES, et al., "Treatment of Psoriasis with Intermittent Short Course Cyclosporin (Neoral.RTM.). A Multicentre Study", British Journal of Dermatology, vol. 136, pp. 527-530, 1997.		
	C38	BIEBER et al. (1981) "Complications in long-term survivors of cardiac transplantation", Transplant Proc. 8(1): 207-211.		
	C39	BIERER, et al. (1988) "T Cell Adhesion Molecules" FASEB J. 2:2584-2590.		
	C40	BIERER et al. (1988) "Expression Of The T-Cell Surface Molecule CD2 And An Epitope-Loss CD2 Mutant To Define The Role Of Lymphocyte Function-Associated Antigen 3 (LFA-3) in T-Cell Activation" Proc. Natl. Acad. Sci. USA 85:1194-1198.		
	C41	BIERER et al. (1989) "A Monoclonal Antibody to LFA-3, the CD2 Ligand, Specifically Immobilizes Major Histocompatibility Complex Proteins" Eur. J. Immunol. 19:661-665.		
	C42	BIERER, B. et al. "Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor", J. Exp. Med. 168: 1145-1156, Sep. 1988.		
	C43	BJERKE, et al., "Acitretin Versus Etretnate in Severe Psoriasis. A double-blind Randomized Nordic Multicenter Study in 168 Patients", Acta Derm Venereol Suppl (Stockh), Vool. 146, pp. 206-207, 1989.		
	C44	BJERRING, et al., "Topical Treatment of Psoriatic Skin with Methotrexate Cream: A Clinical, Pharmacokinetic, and Histological Study", Acta Derm Venereol (Stockh), vol. 66, pp. 515-519, 1986.		
	C45	BOCKENSTEDT et al. (1988) "The CD2 Ligand LFA-3 Activates T Cells But Depends On The Expression And Function Of The Antigen Receptor" J. Immunol. 141:1904-1911.		
	C46	BOEHNCKE, et al., "Differential Expression of Adhesion Molecules on Infiltrating Cells Inflammatory Dermatoses", Journal of American Academy of Dermatology, vol. 26, No. 6, pp. 907-913, 1992.		
	C47	BONIFATI, et al., "Recognition and Treatment of Psoriasis: Special Considerations in Elderly Patients" Drugs & Aging, vol. 12, No. 3, pp. 177-190, 1998.		
	C48	BONNERJEA, et al. "Protein Purification: The Right Step at the Right Time" Bio/Technology 4:955 (1986)		
	C49	BORRONI, et al., "Evidence for CD8+ Cell Increase in Long-Term PUVA-Treated Psoriatic Patients after PUVA Discontinuation", Dermatology, vol. 185, pp. 69-71, 1992.		
	C50	BOS, et al., "Immunologie in de Medische Praktijk. VII. Psoriasis", Ned Tijdschr Geneesk, vol. 141, No. 48, pp. 2334-2338, 1997.		
	C51	BOUHNICK, et al., "Long- term Follow-up of Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine", The Lancet, vol. 347, pp. 215-219, 1996.		

Examiner Signature

/Phillip Gambel/


Date Considered

09/30/2008

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	6	of	33	Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**


Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C52	BOVENSCHEN, et al., "Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis", Arch. Dermatol. Res. 298: 457-463 (2007)		
	C53	BOWIE et al. Deciphering the messages in protein sequences: Tolerance to amini acid substitutions. Science 240:1306-1310, Mar. 1990.		
	C54	BRESSLER, P., et al., "Anti-CD2 Receptor Antibodies Activate the HIV Long Terminal. Repeat in T Lymphocytes," J. Immunol., 147(7), pp. 2290-2294 (Oct. 1, 1991).		
	C55	BROD, S. A. et al., "T-T Cell Interactions Are Mediated by Adhesion Molecules," Eur. J. Immunol., 20, pp. 2259-2268 (1990).		
	C56	BROMBERG et al. (1991) "Anti-CD2 Monoclonal Antibodies Alter Cell-Mediated Immunity In Vivo" Transplantation 51:219-225.		
	C57	BROTTIER, et al., "T Cell Activation Via CD2 [T, gp50] Molecules: Accessory Cells are Required to Trigger T Cell Activation via CD2-D66 Plus CD2-9.6/T11.sub.I Epitopes.sup.I ", The Journal of Immunology, vol. 135(3), pp. 1624-1631, 1985.		
	C58	BROWN et al. (1987) "T2.2 Characterization Of CD2 Epitopes By Western Blotting" in Leukocyte Typing III, A.J. McMichael (ed.) Oxford, England: Oxford University Press, 110-112.		
	C59	BROWN et al. (1989) "The CD2 Antigen Associates With The T-Cell Antigen Receptor CD3 Antigen Complex On The Surface Of Human T Lymphocytes" Nature 339: 551-553.		
	C60	BUCHERRI, et al., "Acitretin Therapy is Effective for Psoriasis Associated with Human Immunodeficiency Virus Infection", Archives of Dermatology, vol. 133, pp. 711-715, 1997.		
	C61	BURDEN, "Management of Psoriasis in Childhood", Clinical and Experimental Dermatology, vol. 24, pp. 341-345;1999.		
	C62	BURNS, et al., "Intralesional Cyclosporine for Psoriasis", Archives of Dermatology, vol. 128, pp. 786-790, 1992.		
	C63	CAMISA, Psoriasis, Blackwell Scientific Publications, 1994, 1.sup.st Ed.		
	C64	CAPON, et al., "Designing CD4 immunoadhesins for AIDS therapy", Nature 337(9): 525-531(1989)		
	C65	CARRERA, et al. "Triggering of co-mitogenic signals in T cell proliferations by anti-LFA-1 (CD18, CD11a), CLA-3, and CD7 monoclonal antibodies", J. Immunol. 141(6):1919-1924 (1988)		
	C66	CATE, et al., "Isolation of the Bovine and Human Genes for Mullerian Inhibiting Substance and Expression of the Human Gene in Animal Cells", Cell, 45, 685-698 (1986).		
	C67	CERDAN, et al., "Prolonged IL-2 receptor $\alpha$ /CD25 expression after T cell activation via the adhesion molecules CD2 and CD28", J. Immunol. 149(7):2255-2261 (1992)		
	C68	CHANDRARATNA, "Tazarotene: The First Receptor-Selective Topical Retinoid for the Treatment of Psoriasis", American Academy of Dermatology, vol. 37, No. 2, pp. S12-S17, 1997.		
	C69	CHANG et al. (1992) "T-Cell Activation Is Potentiated by Cytokines Released by Lesional Psoriatic, but Not Normal, Epidermis" Arch. Dermatol. 128:1479-1785.		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	7	of	33	Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C70	CHAVIN, et al., "Prolongation of allograft and xenograft survival in mice by anti-CD2 monoclonal antibodies", Transplantation, 54(2):286-291 (1992)		
	C71	CHIN, Y.H. et al. "Lymphocyte Recognition of Psoriatic Endothelium: Evidence for a Tissue-Specific Receptor/Ligand Interaction", J. Invest. Dermatol. 93(2) Supplement: 82S-87S (1989).		
	C72	CHISHOLM et al. (1994) "The effects of an immunodulatory LFA3-IgG.sub.I fusion protein on nonhuman primates," Therapeutic Immunology 1: 205-216.		
	C73	CHRISTIANSEN, et al., "Etretinate (Tigason.RTM.) and Betamethasone Valerate (Celeston Valerate.RTM.) in the Treatment of Psoriasis", Dermatologica, vol. 165, pp. 204-207, 1982.		
	C74	CHRISTOPHERS, et al., "The Inflammatory Infiltrate in Psoriasis", Clinics in Dermatology, vol. 13, pp. 131-135, 1995.		
	C75	CHRISTOPHERS, et al., "Cyclosporine in Psoriasis: A Multicenter Dose-Finding Study in Severe Plaque Psoriasis", Therapy, Journal of the American Academy of Dermatology, vol. 26, No. 1, pp. 876-890, 1992.		
	C76	CHURCH, et al., "Genomic Sequencing", Proc. Natl. Acad. Sci. U.S.A., 81, 1991-1995 (1984).		
	C77	CLAYTON et al. (1987) "Murine and Human T11 (CD2) cDNA Sequences Suggest A Common Signal Transduction Mechanism" Eur. J. Immunol. 17: 1367-1370.		
	C78	COHEN, et al., "Immunomodulatory Agents and Other Medical Therapies in Inflammatory Bowel Disease" Current Opinion in Gastroenterology, vol. 11, pp. 321-330, 1995.		
	C79	COLTEN, "Pulmonary Inflammation-A Balancing Act", N Engl J Med. 1997 Apr. 10;336(15):1094-6.		
	C80	COLVIN, et al., "Cellular and Molecular Mechanisms of Allograft Rejection", Ann Rev Med 41:361-375 (1990)		
	C81	CONTI et al., (1990) "Effect of Monoclonal Antibodies on Primate Allograft Rejection" Crit. Rev. Immunol. 10(2): 113-130.		
	C82	CONZELMANN et al. (1986) "Anchoring of membrane proteins via phosphatidylinositol is deficient in two classes of Thy-1 negative mutant lymphoma cells", The EMBO J., vol. 5, No. 12, pp. 3291-3296.		
	C83	COOPER (1990) "Immunoregulation in the Skin" Current Problems in Dermatology 19:69-80.		
	C84	COOPER (1992) "Skin-infiltrating Lymphocytes in Normal and Disordered Skin: Activation Signals and Functional Roles in Psoriasis and Mycosis Fungoides-types Cutaneous T Cell Lymphoma" J. Dermatol. 19:731-737.		
	C85	COOPER et al. (1985) "Effects of ultraviolet radiation on human epidermal cell alloantigen presentation: initial depression of langerhans cell-dependent function is followed by appearance of T6-Dr+ cells that enhance epidermal alloantigen presentation" J. Immunol. 134(1):129-137.		
	C86	COSIMI et al., "In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts.sup.1 " (The Journal of Immunology--June 15, 1990 pp. 4604-4612).		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./**

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	8	of	33	Attorney Docket Number	253780

## OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C87	COSOMI et al.; "Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody" Surgery, 108 (2): 1990 pp. 406-414).		
	C88	Cosimi, et al. "Immunosuppression of Cynomolgus Recipients of Renal Allografts..." Leukocyte Adhesion Molecules (Springer-Verlog 1988) pp. 275-281		
	C89	COSIMI, et al., "Anti-T-Cell Monoclonal Antibodies in Transplantation Therapy", Transplantation Proc. 15(3):1889-1892 (1983)		
	C90	CRISPE, and Mehal, "Strange Brew: T Cells in the Liver" Immunology Today, vol. 17, No. 11, pp. 522-525, 1996.		
	C91	CRONSTEIN, "The Mechanism of Action of Methotrexate", Rheumatic Disease Clinics of North America, vol. 23, No. 4, pp. 739-755, 1997.		
	C92	CUELAR, et al., "Psoriatic Arthritis Current Developments" J. Florida M.A. 82(5):338-342 (1995)		
	C93	CUNNINGHAM and HARRIS (1992) "Antibody engineering--how to be human" TIBTECH 10.		
	C94	CUNNINGHAM et al., "Neural Cell Adhesion Molecule: Structure, Immunoglobulin-Like Domains, Cell Surface Modulation, and Alternative RNA Splicing," Science, 236, pp. 799-806 (1987).		
	C95	CURTIS, et al. (1992) "The Nature of Science" in Biology, 5.sup.th ed. (Worth Publishers, Inc.): 14-15		
	C96	DAILEY, et al., "Sequences in the Polyomavirus DNA Regulatory Region Involved in Viral DNA Replication and Early Gene Expression," J. Virology, 54 (3), pp. 739-749 (Jun. 1985).		
	C97	DAMLE, et al., "Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule 1 or vascular cell adhesion molecule 1 induces functional expression of CTLA-4, a second receptor for B7" J. Immunol (1994)		
	C98	DAMLE, et al., "Stimulation of cloned human T lymphocytes via the CD3 or CD28 molecules induces enhancement in vascular endothelial permeability to macromolecules with participation of type -1 and type-2 intercellular adhesion pathways" Eur. J. Immunol. 20 (9):1995-2003 (1990)		
	C99	DAMLE, N., et al., "Differential Costimulatory Effects of Adhesion Molecules B7, ICAM-1, LFA-3, and VCAM-1 on Resting and Antigen-Primed CD4.sup.+ T Lymphocytes" The Journal of Immunology, vol. 148, 1985-1992, No. 7 (Apr. 1, 1992):.		
	C100	DANIELIAN, et al., "The Tyrosine Kinase Activity of p56.sup.kk is Increased in Human T Cells Activated via CD2", European Journal of Immunology, vol. 21, pp. 1967-1970, 1991.		
	C101	DAVIES, and Morris, "Physiological Parameters in Laboratory Animals and Humans" Pharmaceutical Research, vol. 10, No. 7, pp. 1093-1095, 1993.		
	C102	DAWE, et al., "Narrow-Band (TL-01) Ultraviolet B Phototherapy for Chronic Plaque Psoriasis: Three Times of Five Times Weekly Treatment?" British Journal of Dermatology, vol. 1, No. 38, pp. 833-839, 1998.		
	C103	DECKERT, et al., "CD59 molecule: A second ligand for CD2 in T cell adhesion", Eur. J. Immunol. 22:2943-2947 (1992)		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 33

**Complete if Known**

Application Number	10/588,323
Filing Date	February 7, 2005
First Named Inventor	MAGILAVY
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C104	DENNING et al. (1987) "Monoclonal Antibodies to CD2 and Lymphocyte Function-Associated Antigen 3 Inhibit Human Thymic Epithelial Cell-Dependent Mature Thymocyte Activation" J. Immunol. 139(8):2573-2578.		
	C105	DENNING et al. (1988) "Purified Lymphocyte Function-Associated Antigen-3 (LFA-3) Activates Human Thymocytes Via The CD2 Pathway" J. Immunol. 141(9): 2980-2985.		
	C106	DENTE, L., et al., "pEMBL: a New Family of Single Stranded Plasmids," Nucleic Acids Research, 11(6), pp. 1645-1655 (1983).		
	C107	Department of Health & Human Services, "International Conference on Harmonisation" Federal Register, vol. 62, No. 222, pp. 61515-61519, 1997.		
	C108	DING et al. (1996) "A novel murine model for the assessment of human CD2-related reagents In Vivo," J. Immunol. 157(5): 1863-1869.		
	C109	DINOWITZ, et al., "Recent Studies on Retrovirus-Like Particles in Chinese Hamster Ovary Cells", Developments in Biological Standardizations, vol. 76, pp. 201-207, 1991.		
	C110	DRAKE, et al., "Guidelines of Care for Psoriasis", Journal of American Academy of Dermatology, vol. 28, No. 4, pp. 632-637, 1993		
	C111	DRISCOLL, et al., "Structure of Domain 1 of Rat T Lymphocyte CD2 Antigen", Nature, vol. 353, pp. 762-765, 1991.		
	C112	DUSTIN et al. (1987) "Purified Lymphocyte Function-Associated Antigen 3 Binds to CD2 And Mediates T Lymphocyte Adhesion" J. Exp. Med. 165(3): 677-692.		
	C113	DUSTIN et al. (1987) "T Cell Activation By LFA-3 and CD2 Antibodies" FASEB J. 45:A1239 (Abstract No. 5484).		
	C114	DUSTIN, and Springer, "Role of Lymphocyte Adhesion Receptors in Transient Interaction and Cell Locomotion" Annual Review of Immunology, vol. 9, pp. 27-66, 1991.		
	C115	DUSTIN, and Springer, "T-Cell Receptor Cross-Linking Transiently Stimulates Adhesiveness Through LFA-1" Nature, vol. 341, pp. 619-624, 1989.		
	C116	DUSTIN, et al., "Anchoring Mechanisms for LFA-3 Cell Adhesion Glycoprotein at Membrane Surface", Nature, vol. 329, 846-848, 1987.		
	C117	DUSTIN, et al., "Low Affinity Interaction of Human or Rat T Cell Adhesion Molecule CD2 with Its Ligand Aligns Adhering Membranes to Achieve High Physiological Affinity", The Journal of Biological Chemistry vol. 272, No. 49, pp. 30889-30898, 1997.		
	C118	DUSTIN, M. L., et al., "Correlation of CD2 Binding and Functional Properties of Multimeric and Monomeric Lymphocyte Function-Associated Antigen 3," J. Exp. Med., 169, pp. 503-517 (Feb. 1989).		
	C119	DUVIC, et al., "Molecular Mechanisms of Tazarotene Action in Psoriasis", Journal of American Academy of Dermatology, vol. 37, No. 2, pp. S18-S24, 1997.		
	C120	ECONOMIDOU, et al., "Effects of Cyclosporin A on Immune Activation Markers in Patients with Active Psoriasis", Dermatology, vol. 199, pp. 144-148, 1999.		
	C121	EDELHOCH, "Spectroscopic Determination of Tryptophan and Tyrosine in Proteins" Biochemistry, vol. 6, No. 7, pp. 1948-1954, 1967.		
	C122	EHMANN, and Voorhees, "Effect of Oral Synthetic Retinoids on Keratinizing Disorders", Journal of American Academy of Dermatology, vol. 6, No. 4, pp. 692-696, 1982.		

Examiner Signature

/Phillip Gambel/

Date Considered

09/30/2008

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

10

of

33

**Complete if Known**

Application Number 10/588,323

Filing Date February 7, 2005

First Named Inventor MAGILAVY

Group Art Unit 1644

Examiner Name Unassigned

Attorney Docket Number 253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C123	EKBORN, et al., "Crohn's Disease After In-Utero Measles Virus Exposure", The Lancet, vol. 348, pp. 515-517, 1996.		
	C124	ELDER, et al., "Efficacy and Pharmacokinetics of Two Formulations of Cyclosporine A in Patients with Psoriasis" Journal of Clinical Pharmacology, vol. 35, pp. 865-875, 1995.		
	C125	ELLIS, "Quality of Life Results from a Randomized Double Blind Multi Center Dose Response study of LFA3TIP in patients with Chronic Plaque Psoriasis" Am Acad Dermatol. 58th Ann Meeting March 10-15 2000. (Abstract)		
	C126	ELLIS, et al., "Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial", The New England Journal of Medicine vol. 324, No. 5, pp. 276-284, 1991.		
	C127	ELLIS, et al., "Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes", The New England J. Med. 345(4):248-255 (2001)		
	C128	ENE, V. and N. D. Zinder, "Interference Resistant Mutants of Phage f1," Virology, 122, pp. 222-226 (1982).		
	C129	EWE, et al., "Azathioprine and Prednisolone for Active Crohn Disease", ACP Journal Club, 1994, Annals of Internal Medicine 120/2 Suppl. 1 (13).		
	C130	EZEKOWITZ, et al., "The Interferons: Basic Biology and Therapeutic Potential" in Therapeutic Immunology, edited by Austen et al., (Blackwell Science, Cambridge, MA, 1996) 249-263.		
	C131	FARBER, "Juvenile Psoriasis: Early Interventions Can Reduce Risks for Problems Later" Postgraduate Medicine vol. 103, No. 4, pp. 89-100, 1998.		
	C132	FARBER, et al. "Psoriasis: A Disease of the Total Skin" Journal of American Academy of Dermatology, vol. 12(1), pp. 150-156, 1985.		
	C133	FAULDS, et al., "Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders", Drugs, vol. 45, No. 6, pp. 953-1040, 1993.		
	C134	FEAGAN, et al., "Methotrexate for the Treatment of Crohn's Disease" The New England Journal of Medicine, vol. 332(5), pp. 292-297, 1995.		
	C135	Feagan, et al., "Methotrexate Improved Symptoms in Chronic Active Crohn Disease", ACP Journal Club, 1995, Jul.-Aug.;123(1) 9.		
	C136	FEAGAN, et al., "Therapeutics and Inflammatory Bowel Disease: A Guide to the Interpretation of Randomized Controlled Trials" Gastroenterology, vol. 110, pp. 275-283, 1996.		
	C137	FELDMAN, et al., "The Economic Impact of Psoriasis Increases with Psoriasis Severity" Journal of American Academy of Dermatology, vol. 37(4), pp. 564-569, 1997.		
	C138	FELDMAN, et al., "The Self-Administered Psoriasis Area and Severity Index is Valid and Reliable", Journal of Investigative Dermatology, vol. 106, pp. 183-186, 1996.		
	C139	FERGUSON et al. (1988) "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures", Ann. Rev. Biochem., vol. 57, pp. 285-320.		
	C140	FERACILLI, et al., "Effects of cyclosporine on joint damage in rheumatoid arthritis", Clin Exp. Rheum. 15 (Supp 17):S83-S89 (1997)		
	C141	Ffrench-Constant, "Pathogenesis of Multiple Sclerosis", The Lancet, vol. 343, pp. 272-278, 1994.		

Examiner Signature

/Phillip Gambel/

Date Considered

09/30/2008

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./



Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	11	of	33	Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**


Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C142	FINDLAY "Purification of Membrane Proteins" Ch. 4 in Protein Purification Applications, A Practical Approach (Harris and Angel, eds) 1990 (cited for argument)		
	C143	FINDLAY, and Khan, "Dermatology Life Quality Index (DLQI): A Simple Practical Measure for Routine Clinical Use", Clinical and Experimental Dermatology, vol. 19, pp. 210-216, 1993.		
	C144	FINZI, et al., "A Clinical Survey of Psoriasis in Italy: 1.sub.st AISP Report" Journal of the European Academy of Dermatology and Venereology, vol. 10, pp. 125-129, 1998.		
	C145	FINZI, et al., "Cyclosporin versus Etretinate: Italian Multicenter Comparative Trial in Severe Plaque-Form Psoriasis", Dermatology, vol. 187(suppl 1), pp. 8-18, 1993		
	C146	FIRST, "Transplantation in the Nineties", Transplantation 53(1):1-11 (1992)		
	C147	FISHEL, et al. "The cellular response to xenotransplantation", Curr. Surg. 47(5):345-347 (1990)		
	C148	FISHER, "T cell adhesion", J. Exp. Clin. Hematol. 32:49-51 (1990)		
	C149	FLEISCHER, Jr., et al., "Disease Severity Measures in a Population of Psoriasis Patients: The Symptoms of Psoriasis Correlate with Self-Administered Psoriasis Area Severity Index Scores", Journal of Investigative Dermatology, vol. 107, No. 1, pp. 26-29, 1996.		
	C150	FLEISCHER, Jr., et al., "Patient Measurement of Psoriasis Disease Severity with a Structured Instrument" Journal of Investigative Dermatology, vol. 102, No. 6, pp. 967-969, 1994.		
	C151	FORTUNE, et al., "Quality of Life in Patient with Psoriasis: the Contribution of Clinical Variables and Psoriasis-Specific Stress", British Journal Of Dermatology, vol. 137, pp. 755-760, 1997.		
	C152	FOX, "The Role of T Cells in the Immunopathogenesis of Rheumatoid Arthritis", Arthritis & Rheumatism, vol. 40, No. 4, pp. 598-609, 1997.		
	C153	GAMACHE et al. (1996) "Pharmacokinetics of LFA3TIP, an immunoglobulin fusion protein, in male and female baboons," Pharmaceutical Research 13 (9 Sup.): s399 (Abstract).		
	C154	GASGOIGNE et al., "Secretion of a chimeric T-cell receptor-immunoglobulin protein", 1987, P.N.A.S. USA, vol. 84:2936-2940.		
	C155	GEIDER, K., et al., "A Plasmid Cloning System Utilizing Replication and Packaging Functions of the Filamentous Bacteriophage fd," Gene, 33, pp. 340-349 (1985).		
	C156	Genmab Press release 48/2002 "HuMAX CD-4 in combination therapy not effective in Rheumatoid Arthritis"		
	C157	GEORGOURAS, et al. "Systemic Treatment of Severe Psoriasis", Australasian Journal of Dermatology, vol. 38, pp. 171-182, 1997.		
	C158	GIMENEZ-ARNAU, et al., "Psoriasis: bases de actuacion terapeutica", Act. Dermatolog. 3:159-171(1998)		
	C159	GIORGI, et al, "Immunosuppressive Effect and Immunogenicity of OKT11A monoclonal antibody in monkey allograft recipients", Transplantation Proc. 15(1):639-642 (1983)		
	C160	GISMONDI, et al., "Triggering through CD16 or Phorbol Esters Enhances Adhesion of NK Cells to Laminin via Very Late Antigen 6", Journal of Experimental Medicine, vol. 176, pp. 1251-1257, 1992.		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Examiner Name	Unassigned				
Attorney Docket Number	253780				
Sheet	12	of	33		

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No**	
	C161	GOEBEL, et al., "Drug Trials in Inflammatory Bowel Diseases 1993-1995: A Survey Conducted by the IOIBD", Inflammatory Bowel Diseases, vol. 2, pp. 265-267, 1996.			
	C162	GOEDKOOOP et al., "Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis", Arch. Dermatol. Res. 295:465-473 (2004)			
	C163	GOLDMAN, et al., "OKT3-Induced Cytokine Release Attenuation by High-Dose MethylPrednisolone", Lancet. Sep. 30, 1989;2(8666):802-3.			
	C164	GOLLNICK, et al., "Acitretin* versus Etretnate in Psoriasis: Clinical and Pharmacokinetic Results of a German Multicenter Study", Journal of American Academy of Dermatology, vol. 19, No. 3, pp. 458-468, 1988.			
	C165	GOLLOB, et al., "CD2 Regulates Responsiveness of Activated T Cells to Interleukin 12", Journal of Experimental Medicine, vol. 182, pp. 721-731, 1995.			
	C166	GONZALES-RAMOS et al. (1992) "APC-Targeted Immunointervention in Psoriasis: Blockade of LFA-3-CD2 and ICAM 1-LFAI Ligand Pairing Blocks Autoreactivity to Lesional Epidermis" Clinical Research 40(2):500A.			
	C167	GORDON, et al., "Treatment of psoriasis with alefacept", Arch. Dermatol. 139: 1563-1570 (2003)			
	C168	GOTTLIEB, "The Challenges of Treating Moderate to Severe Psoriasis", International Journal of Dermatology, vol. 36(suppl 1), pp. 41-44, 1997.			
	C169	GREAVES, and Weinstein, "Treatment of Psoriasis", The New England Journal of Medicine, vol. 332, No. 9, pp. 581-588, 1995.			
	C170	GREENBERG, et al., "Oral Budesonide for Active Crohn's Disease", The New England Journal of Medicine, vol. 331, No. 13, pp. 836-845, 1994.			
	C171	GREGERSEN, et al., "A CD4: immunoglobulin fusion protein with antiviral effects against HIV", Arch. Virol. 111:29-43 (1990)			
	C172	GROSSMAN, et al., "A Novel Therapeutic Approach to Psoriasis with Combination Calcipotriol Ointment and Very-Low-Dose Cyclosporine: Results of a Multicenter Placebo-Controlled Study", Journal of American Academy of Dermatology, vol. 31, No. 1, pp. 68-74, 1994.			
	C173	GROSSMAN et al., "Long-term Safety of Cyclosporine in the Treatment of Psoriasis", Archives of Dermatology, vol. 132, pp. 623-629, 1996.			
	C174	GROSVELD, et al., "The Construction of Cosmid Libraries Which Can Be Used to Transform Eukaryotic Cells", Nucl. Acids. Res., 10(21), 6715-6732 (1982).			
	C175	GUBLER, et al., "A Simple and Very Efficient Method for Generating cDNA Libraries", Gene, 25, 263-269 (1983).			
	C176	GUCKIAN, et al., "Immunomodulation at the Initiation of Phototherapy and photochemotherapy", Photodermatology, Photoimmunology & Photomedicine, vol. 11, pp. 163-169, 1995.			
	C177	GULLIVER, et al., Increased Bioavailability and Improved Efficacy, in Severe Psoriasis, of a New Microemulsion Formulation of Cyclosporin*, British Journal Of Dermatology, vol. 135(suppl 48), pp. 35-39, 1996.			
	C178	GUZZO, "Recent Advances in the Treatment of Psoriasis", Dermatologic Clinics, vol. 15, No. 1, pp. 59-68, 1997.			
	C179	HAFLER, et al., "Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis", J. Immunol. 141(1):131-138 (1988)			
Examiner Signature		/Phillip Gambel/	Date Considered	09/30/2008	

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(4).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	13	of	33	Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C180	HALE, et al. "Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation", J. Immunol. 149(12):3809-3816 (1992)		
	C181	HAMBLIN, "From Dendritic Cells to Tumour Vaccines", The Lancet, vol. 347, pp. 705-706, 1996.		
	C182	HANAUER, "Inflammatory Bowel Disease", Drug Therapy, vol. 334, No. 13, pp. 841-848, 1996.		
	C183	HANAUER, "Medical Therapy of Ulcerative Colitis" The Lancet, vol. 342, pp. 412-417, 1993.		
	C184	HARDMAN, et al., "Active Psoriasis and Profound CD4.sup.+ Lymphocytopenia", British Journal Of Dermatology, vol. 136, pp. 930-932, 1997.		
	C185	HARRIS and Emery (1993) "Therapeutic antibodies--the coming of age" TIBTECH 11: 42-44.		
	C186	HAWKE, et al., "Autoimmune T Cells in Myasthenia Gravis: Heterogeneity and Potential for Specific Immunotargeting", Immunology Today, vol. 17, No. 7, pp. 307-311, 1996.		
	C187	HAWKES, et al., "A Dot-Immunobinding Assay for Monoclonal and Other Antibodies", Anal. Biochem., 119, 142-147 (1982).		
	C188	HAYNES, B.F. et al. "Synovial microenvironment-T cell interactions", Arthritis and Rheum. 31 (8): 947-955 (1988).		
	C189	HE et al., "Phosphatidylinositol is Involved in the Membrane Attachment of NCAM-120, the Smallest Component of the Neural Cell Adhesion Molecule," EMBO Journal, 5, (10), pp. 2489-2494 (1986).		
	C190	HEBEL, et al., "Suppression of the immune response by a soluble complement receptor of B lymphocytes", Science 254(5028):102-105 (1991) (cited for argument)		
	C191	HEIJ (La Heij), et al., "Adhesion molecules in iris biopsy specimens from patients with uveitis", Br. J. Ophthamol. 82(4):432-437 (1998)		
	C192	HENSELER, "The Genetics of Psoriasis", Journal of American Academy of Dermatology, vol. 37, No. 2, pp. S1-S11, 1997.		
	C193	HENSELER, and Christophers, "Disease Concomitance in Psoriasis", Journal of American Academy of Dermatology, vol. 32, pp. 982-986, 1997.		
	C194	HENSELER, and Christophers, "Psoriasis of Early and Late Onset: Characterization of Two Types of Psoriasis Vulgaris", Journal of American Academy of Dermatology, vol. 13, No. 3, pp. 450-456, 1995.		
	C195	HERBIN, et al., "Automated Registration of Dissimilar Images: Application to Medical Imagery", Computer Vision, Graphics, and Image Processing, vol. 47, pp. 77-88, 1989.		
	C196	HEWICK, et al., "A Gas-Liquid Solid Phase Peptide and Protein Sequencer", J. Biol. Chem., 256(15), 7990-7997 (1981).		
	C197	HIRAMINE, et al., "Differential Effect of Cyclosporine in Vivo on the Distribution of T cell Subsets in the Thymus, Spleen, and Lymph Nodes", Transplantation, vol. 47, No. 3, pp. 499-503, 1989.		
	C198	HIRANO, et al., "Individual Pharmacodynamics Assessed by Antilymphocyte Action Predicts Clinical Cyclosporine Efficacy in Psoriasis", Clinical Pharmacology & Therapeutics, vol. 63, No. 4, pp. 465-470, 1998.		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	14	of	33	Attorney Docket Number	253780

## OTHER - NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C199	HO, et al., "Intermittent Short Courses of Cyclosporin (Neoral.RTM.) for Psoriasis Unresponsive to Topical Therapy: A 1-Year Multicentre, Randomized Study", British Journal Of Dermatology, vol. 141, pp. 283-291, 1999.		
	C200	HOFFMANN, et al., "Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34", Annals of Rheumatic Diseases, 56 (12) : 716-722 (1997)		
	C201	HOLLSBERG, et al., "Increased protein kinase C activity in human memory T cells", Cell. Immunol. 149(1):170-179 (1993)		
	C202	HONEYMAN, et al., "Low-Dose Cyclosporine a Improves Severe Disabling Psoriasis in Latin America", International Journal of Dermatology, vol. 34, pp. 583-588, 1995.		
	C203	HOOKS et al., "Muromonab CD-3: A review of its pharmacology, pharmacokinetics, and clinical use in transplantation", Pharmacotherapy 11(1):25-37 (1991)		
	C204	HOPKINS, et al., "A double-Blind Controlled Trial of Etretinate (Tigason) and Ibuprofen in Psoriatic Arthritis", Annals of the Rheumatic Diseases, vol. 44, pp. 189-193, 1985.		
	C205	HOWARD et al. (1981) A human T lymphocyte differentiation marker defined by monoclonal antibodies that block E-rosette formation: J. Immunol. 126(6):2117-2122.		
	C206	HUGHES et al. (1990) "Endothelial Cells Augment T Cell Interleukin 2 production by a Contact-Dependent Mechanism involving CD2/LFA-3 Interaction" J. Exp. Med. 171:1453-1467.		
	C207	HUGHES et al. (1990) "The Endothelial Cell As A Regulator Of T-Cell Function" Immunol. Rev. 117, 85-102.		
	C208	HUGOT, et al., "Mapping of a Susceptibility Locus for Crohn's Disease on Chromosome 16", Nature, vol. 379, pp. 821-823, 1996.		
	C209	HUNT, et al., "Generalized Pustular Psoriasis Responsive to PUVA and Oral Cyclosporin Therapy", Australasian Journal of Dermatology, vol. 38, pp. 199-201, 1997.		
	C210	HYMAN (1985) "Cell-surface-antigen mutants of haematopoietic cells", Biochem J., vol. 225, pp. 27-40.		
	C211	IEIRI et al., "Evaluation of the Therapeutic Range of Whole Blood Cyclosporin Concentration in the Treatment of Psoriasis", International Journal of Clinical Pharmacology and Therapeutics, vol. 34, No. 3, pp. 106-111, 1996.		
	C212	IKEMIZU, et al., "Crystal Structure of the CD2-Binding Domain of CD58 (Lymphocyte Function-Associated Antigen 3) at 1.8- Å Resolution", Proceedings of the National Academy of Science, vol. 96, pp. 4289-4294, 1999.		
	C213	INOUE, et al., "Anti-adhesion molecule therapy in Theiler's murine encephalomyelitis virus-induced demyelinating disease", Int. Immunol. 9(12):1837-1847 (1997)		
	C214	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US88/01924, dated October 7, 1988		
	C215	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US89/03652, dated February 7, 1990		
	C216	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US92/02050, dated August 12, 1992		
	C217	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US92/08754, dated June 28, 1993		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO.  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	15	of	33	Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**


Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C218	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US92/08755, dated July 8, 1993		
	C219	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US99/20026, dated May 8, 2000		
	C220	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US02/02314, dated June 11, 2002		
	C221	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US02/21631, dated June 25, 2003		
	C222	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US05/16265, dated October 26, 2005		
	C223	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US05/15531, dated February 24, 2006		
	C224	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US05/03907, dated October 3, 2005		
	C225	INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US05/39070, dated April 27, 2007		
	C226	IP, et al., Structural Characterization of the N-Glycans of a Humanized Anti-CD18 Murine Immunoglobulin G, Archives of Biochemistry and Biophysics, vol. 308, No. 2, pp. 387-399, 1994.		
	C227	ISAACS, et al., "Humanized Anti-CD4 Monoclonal Antibody Therapy of Autoimmune and Inflammatory Disease", Clinical and Experimental Immunology, vol. 110, pp. 158-166, 1997.		
	C228	JEFFERIS, and Lund, "Glycosylation of Antibody Molecules: Structural and Functional Significance", Chemical Immunology, vol. 65, pp 111-113, 1997		
	C229	JEMEC, and Wulf, "The Applicability of Clinical Scoring Systems: SCORAD and PASI in Psoriasis and Atopic Dermatitis", Acta Derm Venereol (Stockholm), vol. 77, pp. 392-393, 1997.		
	C230	JENKINS, et al., "CD28 Delivers A Constitutatory Signal Involved in Antigen-Specific IL-2 Production by Human T Cells", The Journal of Immunology, vol. 147(8), pp. 2461-2466, 1991.		
	C231	JOHNSON, "On Teaching Dermatology to Nondermatologists", Arch Dermatol, vol. 130, pp. 850-852, 1994.		
	C232	JONES, et al., "Crystal Structure at 2.8 Å Resolution of a Soluble Form of the Cell Adhesion Molecule CD2" Nature, vol. 360, pp. 232-239, 1992.		
	C233	JONKER, "Immunosuppressive Therapy by monoclonal anti-T lymphocyte subset antibodies", Leukocyte Typing III (Oxford Univ. Press 1987) pp.923-927.		
	C234	JONKER, et al., "The Influence of OKT8F Treatment on Allograft Survival in Rhesus Monkeys", Transplantation 41(4): 431-435 (1986)		
	C235	JONKER, et al., "Effects of in vivo administration of monoclonal antibodies specific for human T cell subpopulations on the immune system in a rhesus monkey model", Transplantation 35(6): 521-526 (1983)		
	C236	JUNE, "Increases in Tyrosine Phosphorylation are Detectable Before Phospholipase C Activation After T Cell Receptor Stimulation", The Journal of Immunology, vol. 144, No. 5, pp. 1591-1599, 1990.		

Examiner Signature	/Philip Gambel/	Date Considered	09/30/2008
--------------------	-----------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./**

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Examiner Name	Unassigned				
Sheet	16	of	33	Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**


Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C237	KANG, et al., "Calcipotriene-Induced Improvement in Psoriasis is Associated with Reduced Interleukin-8 and Increased Interleukin-10 levels within Lesions", British Journal of Dermatology, vol. 138, pp. 77-83, 1998.		
	C238	KANNER, et al., "CD2/LFA-3 Ligation Induces Phospholipase-C.gamma.1 Tyrosine Phosphorylation and Regulates CD3 Signaling", The Journal of Immunology, vol. 148, No. 7, pp. 2023-2029, 1992.		
	C239	KANTOR, et al., "Double-Blind Bilateral Paired Comparison of 0.05% Halobetasol Propionate Cream and its Vehicle in Patients with Chronic Atopic Dermatitis and Other Eczematous Dermatoses", Journal of the American Academy of Dermatology, vol. 25, No. 6, pp. 1184-1186, 1991.		
	C240	KAPLAN et al. (1987) "Distribution and Turnover of Langerhans Cells During Delayed Immune Responses in Human Skin" J. Exp. Med. 165:763-776.		
	C241	KAPLON et al. (1996) "Short course single agent therapy with an LFA-3-IgG.sub.I fusion protein prolongs primate cardiac allograft survival." Transplantation 61(3): 356-363.		
	C242	KASAHARA, et al., "Role of interleukin 6 for differential responsiveness of naive and memory CD4+ T cells in CD2-mediated activation", J. Exp. Med. 172 (5):1419-1424 (1990)		
	C243	KATO, et al., "CD48 is a Counter-Receptor for Mouse CD2 and is Involved in T Cell Activation", Journal of Experimental Medicine, vol. 176, pp. 1241-1249, 1992.		
	C244	KAUFMAN, and Sharp, "Amplification and Expression of Sequences of Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene", Journal of Molecular Biology, vol. 159, pp. 601-621, 1982.		
	C245	KAUFMAN, and Sharp, "Construction of a Modular Dihydrofolate Reductase cDNA Gene: Analysis of Signals Utilized for Efficient Expression", Molecular and Cellular Biology, vol. 2, No. 11, pp. 1304-1319, 1982.		
	C246	KAWAI, et al., "Intrathecal administration of antibodies against LFA-1 and against ICAM-1 suppresses experimental allergic encephalomyelitis in rats", Cell Immunol. 171(2):262-268 (1996)		
	C247	KELSO, Th1 and Th2 Subsets: Paradigms Lost?, Immunology Today, vol. 16, No. 8, pp. 374-379, 1995.		
	C248	KENT, S. B. H., "Chemical Synthesis of Peptides and Proteins," Ann. Rev. Biochem., 57, pp. 957-989 (1988).		
	C249	KILEEN et al., "The MRC OX-45 Antigen of Rat Leukocytes and Endothelium is in a Subset of the Immunoglobulin Superfamily with CD2, LFA-3 and Carcinoembryonic Antigens", The EMBO Journal, vol. 7, No. 10, pp. 3087-3091, 1988.		
	C250	KIMBALL, Introduction to Immunology, 1983, (Ed.), Macmillan Publishing Co., New York, NY, 1983.		
	C251	KINGSTON, et al., "Etrein Therapy for Severe Psoriasis", Arch Dermatol, vol. 123, pp. 55-58, 1987.		
	C252	KIRKHAM, et al., "Chimeric CD7 monoclonal antibody therapy in Rheumatoid arthritis", J. Rheumatol. 19(9) 1348-1352 (1992).		
	C253	KNOX, et al., "Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides", Blood 77(1):20-30 (1991).		

Examiner Signature	/Philip Gambel/	Date Considered	09/30/2008
--------------------	-----------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Examiner Name	Unassigned				
Attorney Docket Number	253780				
Sheet	17	of	33		


OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No**	
	C254	KOHLER, G. and C. Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," Nature, 256, pp. 495-497 (Aug. 7, 1975).			
	C255	KOLLIAS, "Letter to the Editor: Simple Changes to PUVA Phototherapy May Minimize to the Photocarcinogenic Risks", Photodermatology, Photoimmunology, & Photomedicine, vol. 15, pp. 205, 1999.			
	C256	KOO, "Neoral in Psoriasis Therapy: Toward a New Perspective", International Journal of Dermatology, vol. 36, pp. 25-29, 1997.			
	C257	KOO, "Population-Based Epidemiological Study of Psoriasis with Emphasis on Quality of Life Assessment", Psychodermatology, vol. 14, No. 3, pp. 485-496, 1996.			
	C258	KOO, "Systematic Sequential Therapy of Psoriasis: A New Paradigm for Improved Therapeutic Results", Journal of the American Academy of Dermatology, vol. 41, No. 3, pp. S25-S28, 1999.			
	C259	KOO, et al., "Mometasone Furoate 0.1%-Salicylic Acid 5% Ointment Versus Mometasone Furoate 0.1% Ointment in the Treatment of Moderate-to-Severe Psoriasis: A Multicenter Study", Clinical Therapeutics, vol. 20, No. 2, pp. 283-291, 1998.			
	C260	KOSHY, et al., "Increased Expression of CD40 Ligand on Systemic Lupus Erythematosus Lymphocytes", Journal of Clinical Investigation, vol. 98, No. 3, pp. 826-837, 1996.			
	C261	KOYASU et al. (1990), "Role of Interaction Of CD2 Molecules With Lymphocyte Function-Associated Antigen 3 In T-Cell Recognition of Nominal Antigen" Proc. Natl. Acad. Sci. USA 87: 2603-2607.			
	C262	KRAAN et al., "Alefacept Treatment in Psoriatic Arthritis" Arthritis Rheum. 46(10):2776-2784 (2002)			
	C263	KRAGBALLE, et al., "A Double-Blind Comparison of Acitretin and Etretinate in the Treatment of Severe Psoriasis", Acta Derm Venereol (Stockh), vol. 69, pp. 35-40, 1989.			
	C264	KRANZ et al., "Immunoprecipitation of Cell Surface Structures of Cloned Cytotoxic T Lymphocytes by Clone-Specific Antisera," Proc. Natl. Acad. Sci. U.S.A., vol. 81, pp. 573-77 (1984).			
	C265	KRENSKY (1990) "The Human Cytolytic T Lymphocyte Response to Transplantation Antigens" Pediatric Res. 19(12):1231-1234.			
	C266	KRENSKY et al. (1983) "The Functional Significance, Distribution, And Structure Of LFA-1, LFA-2, And LFA-3: Cell Surface Antigens Associated With CTL-Target Interactions" J. Immunol. 131(2):611-616.			
	C267	KRENSKY et al. (1984) "Human Lymphocyte Function Associated Antigens" Surv. Immunol. Res. 3:39-44.			
	C268	KRUEGER, et al., "Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking", J. Inves. Derm. 115:333 (2000) (Abstract)			
	C269	KRUEGER "Efficacy and Safety results of a phase II trial with LFA3TIP in patients with chronic plaque psoriasis." Am Acad Dermatol. 58th Ann Meeting March 10-15 2000. (Abstract)			
	C270	KRUEGER, and Duvic, "Epidemiology of Psoriasis: Clinical Issues", The Journal of Investigative Dermatology, vol. 102, No. 6, pp. 14S-18S, 1994.			

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Examiner Name	Unassigned				
Attorney Docket Number	253780				
Sheet	18	of	33		

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No**	
	C271	KRUEGER, Efficacy and Safety results of a phase II trial with LFA3TIP in patients with chronic plaque psoriasis. From Gene to Clinic Congress. AMEVIVE™ Breakfast Meeting Dec. 3, 1999 p.1.			
	C272	KRUEGER, et al., "The Safety and Efficacy of Tazarotene Gel, a Topical Acetylenic Retinoid, in the Treatment of Psoriasis", Arch Dermatol, vol. 134, pp. 57-60, 1998.			
	C273	KULLAVANIJAYA, and Kulthanan, "Clinical Efficacy and Side Effects of Acitretin on the Disorders of Keratinization: A One-Year Study", The Journal of Dermatology, vol. 20, pp. 501-506, 1993.			
	C274	KUMAR, et al., "Methotrexate in Childhood Psoriasis", Pediatric Dermatology, vol. 11, No. 3, 271-273, 1994.			
	C275	KUMAR, et al., "Short Term Methotrexate Therapy in Psoriasis", Indian J Med Res, vol. 100, pp. 277-280, 1994.			
	C276	KUPPER, "Immune and inflammatory processes in cutaneous tissues: mechanisms and speculations", J.Clin. Invest. 86:1783-1789 (1990)			
	C277	LABURTE, et al., "Efficacy and Safety of Oral Cyclosporin A (CyA; Sandimmun.RTM.) for Long-Term Treatment of Chronic Severe Plaque Psoriasis", British Journal of Dermatology, vol. 130, pp. 366-375, 1994.			
	C278	LAI et al., "Two Forms of TB236/Myelin-Associated Glyco Protein, a Cell Adhesion Molecule for Postnatal Neural Development, are Produced by Alternative Splicing," Proc. Natl. Acad. Sci. U.S.A., 84, pp. 4337-4441 (1987).			
	C279	LAI et al., "Solid-State Chemical Stability of Proteins and Peptides", Journal of Pharmaceutical Sciences, vol. 88, No. 5, pp. 489-500, 1999.			
	C280	LAMBERT, et al., "Safety and Pharmacokinetics of Hyperimmune Anti-Human Immunodeficiency Virus (HIV) Immunoglobulin Administered to HIV-Infected Pregnant Women and Their Newborns", The Journal of Infectious Diseases, vol. 175, pp. 283-291, 1997.			
	C281	LAMBERT, J. M. et al., "Purified Immunotoxins That Are Reactive With Human Lymphoid Cells," J. Biol. Chem., 260(22), pp. 12035-12041 (1985).			
	C282	LANGFORD, et al., "Use of Cytotoxic Agents and Cyclosporine in the Treatment of Autoimmune Disease", Annals of Internal Medicine, vol. 129, No. 1, pp. 49-58, 1998.			
	C283	LANIGAN, "Treatment of Psoriasis with the Pulsed Dye Laser", Journal of the American Academy of Dermatology, vol. 37, No. 2, pp. 288-289, 1997.			
	C284	LARSON and Springer (1990) "Structure and function of leukocyte integrins" Immunol. Revs. 114:181-217.			
	C285	LAUHARANTA, and Geiger, "A Double-Blind Comparison of Acitretin and Eretinate in Combination with Bath PUVA in the Treatment of Extensive Psoriasis", British Journal of Dermatology, vol. 121, 107-112, 1989			
	C286	LAUHARANTA, et al., "A Clinical Evaluation of the Effects of an Aromatic Retinoid (Tigason), Combination of Retinoid and PUVA, and PUVA Alone in Severe Psoriasis", British Journal of Dermatology, vol. 104, pp. 325-332, 1981.			
	C287	LE et al. (1987) "Anti-LFA-3 Monoclonal Antibody Induced Interleukin 1 (IL 3) Release by Thymic Epithelial (TE) Cells and Monocytes" FASEB J. 46(3):447 Abstract 761.			
	C288	LE et al. (1990) "Ligan Binding to the LFA-3 Cell Adhesion Molecule Induces IL-1 Production By Human Thymic Epithelial Cells" J. Immunol. 144:4541-4547.			
Examiner Signature		/Philip Gambel/	Date Considered	09/30/2008	

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./



Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Examiner Name	Unassigned				
Attorney Docket Number	253780				
Sheet	19	of	33		

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C289	LEBWOHL, et al., "Interactions Between Calcipotriene and Ultraviolet Light", Journal of the American Academy of Dermatology, vol. 37, No. 1, pp. 93-95, 1997.		
	C290	LEBWOHL, et al., "Once-Daily Tazarotene Gel Versus Twice-Daily Flucanide Cream in the Treatment of Plaque Psoriasis", Journal of the American Academy of Dermatology, vol. 38, No. 5, pp. 705-711, 1998.		
	C291	LEDO, et al., "Acitretin (Ro 10-1670) in the Treatment of Severe Psoriasis: A Randomized Double-Blind Parallel Study Comparing Acitretin and Eretinate", International Journal of Psoriasis, vol. 27, No. 9, pp. 656-659, 1988.		
	C292	LEMSTER, et al., "FK 506 Inhibits Cytokine Gene and Adhesion Molecule Expression in Psoriatic Skin Lesions", Annals of New York Academy of Sciences, vol. 696, pp. 250-256, 1993.		
	C293	LENNARD-JONES, "Defining Ulcer Depth in Colitis", The Lancet, vol. 347, pp. 1708, 1996.		
	C294	LETVIN, et al., "T Lymphocyte Surface Antigens in Primates", European Journal of Immunology, vol. 13, pp. 345-347, 1983.		
	C295	LEY, et al., "The T Cell Receptor/CD3 Complex and CD2 Stimulate the Tyrosine Phosphorylation of Indistinguishable Patterns of Polypeptides in the Human T Leukemic Cell Line Jurkat", European Journal of Immunology, vol. 21, pp. 2203-2209, 1991.		
	C296	LI, et al., "Enhancement of B cell responses by the interaction of CD2 with LFA-3", J. Tongji Med. Univ. 12(2):71-74 (1992)		
	C297	LIAO, T., et al., "Modification of Sialyl Residues of Sialoglycoprotein(s) of the Human Erythrocyte Surface," J. Biol. Chem., 248(23), pp. 8247-8253 (Dec. 10, 1973).		
	C298	LICHTIGER, et al., "Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy", The New England Journal of Medicine, vol. 330, No. 26, pp. 1841-1845, 1994.		
	C299	LINDELOF, "Risk of Melanoma with Psoralen/Ultraviolet A Therapy for Psoriasis", Drug Safety, vol. 20, No. 4, pp. 289-297, 1999.		
	C300	LLEWELLYN-SMITH, et al., "Effects of Anti-CD4 Antibody Treatment on Lymphocyte Subsets and Stimulated Tumor Necrosis Factor Alpha Production: A Study of 29 Multiple Sclerosis Patients Entered into a Clinical Trial of cM-T412", Neurology, vol. 48, pp. 810-816, 1997.		
	C301	LORINCZ, "Cutaneous T-Cell Lymphoma (Mycosis Fungoides)", The Lancet, vol. 347, pp. 871-876, 1996.		
	C302	LOTTI, et al., "Neuropeptides and Skin Disorders. The New Frontiers of Neuro-Endocrine-Cutaneous Immunology", International Journal of Dermatology, vol. 38(9), pp. 673-675, 1999.		
	C303	LOW, "Biochemistry of the Glycosyl-Phosphatidylinositol Membrane Protein Anchors," Biochem. J., 244, pp. 1-13 (1987).		
	C304	LOWE, "Initiating Neoral.RTM. Therapy", International Journal of Dermatology, vol. 36(suppl. 1), pp. 30-33, 1997.		
	C305	LUDDEN, "Population Pharmacokinetics", Journal of Clinical Pharmacology, vol. 28, pp. 1059-1063, 1998.		
	C306	MACKAY, et al., "Naive and Memory T Cells Show Distinct Pathways of Lymphocyte Recirculation", J Exp Med. 1990 Mar. 1;171(3):801-17.		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 20 of 33

**Complete if Known**

Application Number	10/588,323
Filing Date	February 7, 2005
First Named Inventor	MAGILAVY
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C307	MAGILAVY, et al., "Targeting CD2 for immunotherapy: results of a phase 1 trial with a LFA-3/IgG Fe fusion protein", Arthritis Rheum.40(9-suppl.): S176 (1997) (Abstract)		
	C308	MAGILAVY, et al., "Pharmacodynamic effects of LFA3TIP (Amevive) in patients with chronic plaque psoriasis (CPP) : Selective modulation of CD45RO+lymphocytes", J. Invest. Dermatol 112(4):609 (1999) (Abstract)		
	C309	MAHRLE, et al., "Anti-Inflammatory Efficacy of Low-Dose Cyclosporin A in Psoriatic Arthritis. A Prospective Multicentre Study", British Journal of Dermatology, vol. 135, pp. 752-757, 1996.		
	C310	MAJEAU et al. (1994), "Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses," J. of Immunol. 152 (6): 2753-2767 (1994).		
	C311	MAJEAU, et al., "Low Affinity Binding of an LFA-3/IgG1 Fusion Protein to CD2+ T Cells is Independent of Cell Activation", Cell Adhesion and Communication, vol. 7, No. 3, pp. 267-279, 1999.		
	C312	MAJEWSKI, et al., "Papillomavirus and Autoimmunity in Psoriasis", Immunology Today, vol. 20, No. 10, pp. 475-476, 1999.		
	C313	MAKGOBA et al. (1989) "The CDA2-LFA-3 And LFA-1-ICAM Pathways: Relevance to T-Cell Recognition" Immunol. Today 10(12):417-422.		
	C314	MAKGOBA et al., "Human T Cell Rosetting is Mediated by LFA-3 on Autologous Erythrocytes," Journ. Immunol., vol. 138(11), pp. 3587-89 (1987).		
	C315	MANIATIS, et al., "Extraction, Purification, and Analysis of mRNA from Eukaryotic Cells", Molecular Cloning, A Laboratory Manual187-209 (Cold Spring Harbor Laboratory, 1982).		
	C316	MARCH, et al., "A Simplified Method for Cyanogen Bromide Activation of Agarose for Affinity Chromatography", Anal. Biochem., 60, 149-152 (1974).		
	C317	MARTZ and Gromkowski (1985) "Lymphocyte Function-Associated Antigens: Regulation of Lymphocyte Adhesions In Vitro And immunity In Vivo" Mechanisms of Cell-Mediated Cytotoxicity II (Plenium Press, 1985) pp291-310.		
	C318	MATIS (1990) "The molecular basis of T-cell specificity" Ann. Rev. Immunol. 8:65-82.		
	C319	MATSUYAMA, et al., "The Quantitative and Qualitative Defect of CD4+ CD45RO+ Memory-Type T Cells are Involved in the Abnormality of TH1 Immunity in Atopic Dermatitis Patients", Clinical and Experimental Allergy, vol. 29, pp. 687-694, 1999.		
	C320	MAXAM et al., "Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages", Methods in Enzymology, 65:499-560 (Academic Press,1980).		
	C321	MAXAM, et al., "A New Method for Sequencing DNA", Proc. Natl. Acad. Sci., 74, 560-564 (1977).		
	C322	MAZZANTI, et al., "Methotrexate and Cyclosporin Combined Therapy in Severe Psoriatic Arthritis. A Pilot Study", Acta Derm Venereol (Stockh), Suppl. 186, pp. 116-117, 1994.		
	C323	McFARLAND, "Complexities in the Treatment of Autoimmune Disease", Science, vol. 274, pp. 2037-2038, 1996.		
	C324	MEFFERT, and Sonnichsen, "Acitrecin in the Treatment of Severe Psoriasis: A Randomized Double-Blind Study Comparing Acitrecin and Etretnate", Acta Derm Venereol (Stockh), Suppl.146, pp. 176-177, 1989.		

Examiner Signature

/Phillip Gambel/

Date Considered

09/30/2008

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 21 of 33

**Complete if Known**

Application Number	10/588,323
Filing Date	February 7, 2005
First Named Inventor	MAGILAVY
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C325	MEFFERT, et al., "Low-Dose (1.25 mg/kg) Cyclosporin A: Treatment of Psoriasis and Investigation of the Influence on Lipid Profile", Acta Derm Venereol (Stockh), vol. 77, pp. 137-141, 1997.		
	C326	MEIER et al (1995) "Immunomodulation by LFA3TIP, an LFA-3/IgG.sub.I fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers," Therapeutic Immunology 2(2): 159-171.		
	C327	MEINGASSNER, et al., "A Novel Anti-Inflammatory Drug, SDZ ASM 981, for the Topical and Oral Treatment of Skin Diseases: In Vivo Pharmacology", British Journal of Dermatology, vol. 137, pp. 568-576, 1997.		
	C328	MENTER, and Barker, "Psoriasis Practice", The Lancet, vol. 338, pp. 231-234, 1991.		
	C329	Merck Manual, Seventeenth Ed. Pp 303-313, 448, 725-729, 1474-1476		
	C330	Mesalamine Study Group, "An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis: A Randomized Placebo-Controlled Trial", Annals of Internal Medicine, vol. 124, pp. 204-211, 1996.		
	C331	MEUER et al. (1984) "An Alternative Pathway of T Cell Activation: A Functional Role for the 50 kd TII Sheep Erythrocyte Receptor Protein" Cell 36:897-906.		
	C332	MEUER et al. (1984) "The human T-cell receptor" Ann. Rev. Immunol. 2:23-50.		
	C333	MEUER et al. (1989) "The Alternative Pathway of T Cell Activation: Biology, Pathophysiology, and Perspectives for Immunopharmacology" Clin. Immunol. Immunopath. 50:S133-S138.		
	C334	MICHLER, et al. "Pretransplant blood transfusion in a primate cardiac xenograft model", Curr. Surg. 44(1):42-45 (1987)		
	C335	MICHLER, et al., "Technique for primate heterotopic cardiac xenotransplantation", J. Med. Primatol. 14:357-362 (1985)		
	C336	MICHLER, et al., "Prolongation of primate cardiac xenograft survival with cyclosporine", Transplantation 44(5):632-636 (1987)		
	C337	MIKAYAMA, et al., "Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor", PNAS 90:10056-10060 (1993)		
	C338	MILLER et al. (1993) "Specific interaction of lymphocyte function associated antigen 3 with CD2 can inhibit T cell responses," J. Exp. Med. 178: 211-222.		
	C339	MOINGEON et al. (1989) "The Structural Biology of CD2" Immunol. Rev. 111:111-144.		
	C340	MOINGEON et al. (1989), "CD2-mediated adhesion facilitates T lymphocyte antigen recognition function," Nature 339: 312-339.		
	C341	MOINGEON et al. (1991) "Complementary Roles For CD2 And LFA-1 Adhesion Pathways During T Cell Activation" Eur. J. Immunol. 21:605-610.		
	C342	MORDENTI, "Forecasting Cephalosporin and Monobactam Antibiotic Half-Lives in Humans from Data Collected in Laboratory Animals", Antimicrobial Agents and Chemotherapy, vol. 27, No. 6, pp. 887-891, 1985.		
	C343	MORELAND, et al. "Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis", Arthritis and Rheumatism 36(3) (1993)		
	C344	MORELAND, et al., "Biological Agents for Treating Rheumatoid Arthritis", Arthritis and Rheumatism, vol. 40, No. 3, pp. 397-409, 1997		

Examiner Signature

/Phillip Gambel/

Date Considered

09/30/2008

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	22	of	33	Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**


Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C345	MORISON, et al., "Consensus Workshop on the Toxic Effects of Long-Term PUVA Therapy" Arch Dermatol, vol. 134, pp. 595-598, 1998.		
	C346	MORONEY, S. E., et al., "Modification of the Binding Site(s) of Lectins by an Affinity Column Carrying an Activated Galactose-Terminated Ligand," Biochemistry, 26, pp. 8390-8398 (1987).		
	C347	MORRISON, S. L., "Transfectomas Provide Novel Chimeric Antibodies," Science, 229, pp. 1202-1207 (Sep. 20, 1985).		
	C348	MOSMANN, et al., "The Expanding Universe of T-Cell Subsets: Th1, Th2 and More", Immunology Today, vol. 17, No. 3, pp. 138-145, 1996.		
	C349	MROWIETZ, et al., "Long-Term Maintenance Therapy with Cyclosporine and Posttreatment Survey in Severe Psoriasis: Results of a Multicenter Study", Journal of the American Academy of Dermatology, vol. 33, No. 3, pp. 470-475, 1995.		
	C350	MUCHENBERGER, et al., "The Combination of Oral Acitrecin and Bath PUVA for the Treatment of Severe Psoriasis", British Journal of Dermatology, vol. 137, pp. 587-589, 1997.		
	C351	MULLIGAN et al., "Selection for Animal Cells that Express the Escherichia Coli Gene Coding for Xanthine-Guanine Phosphoribosyltransferase", Proc. Natl. Acad. Sci. U.S.A., 78:2072-2076 (1981).		
	C352	MURRAY, et al., "A 12-Month Treatment of Severe Psoriasis with Acitrecin: Results of a Canadian Open Multicenter Study", Journal of the American Academy of Dermatology, vol. 24, No. 4, pp. 598-602, 1991.		
	C353	MUSSI, et al., "Serum TNF-Alpha Levels Correlate with Disease Severity and are Reduced by Effective Therapy in Plaque-Type Psoriasis", J Biol Regul Homeost Agents, vol. 11, No. 3, pp. 115-118, 1997.		
	C354	NAIR, et al., "Evidence for Two Psoriasis Susceptibility Loci (HLA and 17q) and Two Novel Candidate Regions (16q and 20p) by Genome-Wide Scan", Human Molecular Genetics, vol. 6, No. 8, pp. 1349-1356, 1997.		
	C355	NAKAKURA, et al., "Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion", Transplantation 55(2):412-417 (1993)		
	C356	NALDI, et al., "Analytical Epidemiology in Psoriasis", Journal of Investigative Dermatology, vol. 102, No. 6, pp. 19S-23S, 1994.		
	C357	NATHAN et al. (1986) "Local and Systemic Effects of Intradermal Recombinant Interferon-gamma in Patients with Lepromatous Leprosy" New Eng. J. Med. 315(1):6-15.		
	C358	NEUBERGER et al., "Recombinant antibodies possessing novel effector functions", 1984, Nature, vol. 312:604-608.		
	C359	NGO et al. "Computational complexity, protein structure prediction, and the Levinthal paradox" in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al. (Ed.), Birkhauser, Boston, MA, pp. 433 and 492-495, 1994.		
	C360	NICHOLAS, et al., "CD4 antibody treatment of severe psoriasis", Lancet 338:321 (1991)		
	C361	NICKOLOFF, "The Cytokine Network in Psoriasis", Arch Dermatol, vol. 127, pp. 871-884, 1991.		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./**

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Examiner Name	Unassigned				
Attorney Docket Number	253780				
Sheet	23	of	33		

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No**	
	C362	NICKOLOFF, et al., "Accessory Cell Function of Keratinocytes for Superantigens: Dependence on Lymphocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction", The Journal of Immunology, vol. 150, No. 6, pp. 2148-2159, 1993.			
	C363	NICKOLOFF, et al., "Cytokine Networks: Immunobiology Surfaces", The Journal of NIH Research, vol. 3, pp. 71-74, 1991.			
	C364	NISHIBU, et al., "Overexpression of Monocyte-Derived Cytokines in Active Psoriasis: A Relation to Coexistent Arthropathy", Journal of Dermatological Science, vol. 21, pp. 63-70, 1999.			
	C365	NOURI et al. (1990) "Selective and non-selective loss of immunoregulatory molecules (HLA-A,B,C antigens and LFA-3) in transitional cell carcinoma" J. Br. Cancer 62:603-606.			
	C366	O'GORMAN, et al., "Genetic Polymorphisms associated with clinical improvement of chronic plaque psoriasis after treatment with alefacept", J. Inves. Derm. 124(4): A40 (2005) (Abstract)			
	C367	OKAYAMA, et al., "High-Efficiency Cloning of Full-Length cDNA", Mol. Cell. Biol., 2(2): 161-170 (1982).			
	C368	OLIVIERI, et al., "Therapy with Cyclosporine in Psoriatic Arthritis", Seminars in Arthritis and Rheumatism, vol. 27, No. 1, pp. 36-43, 1997.			
	C369	OSBAND et al. (1990) "Problem in the investigational Study and Clinical Use of Cancer Immunotherapy" Immunology today 11(6): 193-195.			
	C370	OSBORN et al. (1995), "Amino acid residues required for binding of lymphocyte function-associated antigen 3 (CD58) to its counter-receptor CD2," J. Exp. Med. 181(1): 429-434.			
	C371	PARK, and Youn, "Factors Influencing Psoriasis: An Analysis Based upon the Extent of Involvement and Clinical Type", The Journal of Dermatology, vol. 25, pp. 97-102, 1998.			
	C372	PATEL, et al., "Compatibility of Calcipotriene with Other Topical Medications", Journal of the American Academy of Dermatology, vol. 38, No. 6, pp. 1010-1011, 1998.			
	C373	PAVLI, et al., "Inflammatory Bowel Disease: Germs or Genes?", The Lancet, vol. 347, pp. 1198, 1996.			
	C374	PEARSON, et al., "Azathioprine and 6-Mercaptopurine in Crohn Disease: A Meta-Analysis", Annals of Internal Medicine, vol. 122, pp. 132-142, 1995.			
	C375	PECKHAM, et al., "The Treatment of Severe Psoriasis", Arch Dermatol, vol. 123, pp. 1303-1307, 1987.			
	C376	PENG, et al., "Ligation of CD2 provides a strong helper signal for the production of the type 2 cytokines", Cell. Immunol., 181(1):76-85 (1997)			
	C377	PEPINO et al. (1989) "Primate Cardiac Allo- and Xenotransplantation: Modulation of the Immune Response with Photochemotherapy" Eur. Surg. Res. 21:105-113.			
	C378	PEPINSKY et al. (1991), "The increased potency of cross-linked lymphocyte function-associated antigen-3 (LFA-3) multimers is a direct consequence of changes in valency," J. Biol Chem. 266(27): 18244-18249.			
	C379	PEPINSKY, et al., "Purification and Partial Sequence Analysis of a 37-kDA Protein that Inhibits Phospholipase A.sub.2 Activity from Rat Peritoneal Exudates", J. Bio. Chem., 261(9), 4239-4246 (1986).			
Examiner Signature		/Phillip Gambel/	Date Considered	09/30/2008	

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Examiner Name	Unassigned				
Sheet	24	of	33	Attorney Docket Number	253780

## OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C380	PETERSON (1987) "Monoclonal Antibody And Ligand Binding Sites Of The T Cell Erythrocyte Receptor (CD2)" Nature 329:842-846.		
	C381	PETERSON, A. S., "Genetic and Biochemical Analysis of CD2, LFA-3 Interaction," In Genetic Analysis of CD2/LFA and CD4/HIV Interactions, Chapter 1, pp. 1-13, Figure 1A (Harvard University, Cambridge, Massachusetts 1988).		
	C382	PETTIT, "Oral Retinoid for Psoriasis: A Report of a Double Blind Study", Acta Derm Venereol Suppl (Stockh): 1979;59(85):133-6.		
	C383	PETZELBAUER, et al., "Cyclosporin A Suppresses ICAM-1 Expression by Papillary Endothelium in Healing Psoriatic Plaques", The Journal of Investigative Dermatology, vol. 96, No. 3, pp. 362-386, 1991.		
	C384	PICKER et al. (1990) "A Unique Phenotype of Skin-associated Lymphocytes in Humans" Am. J. Path. 136(5):1053-1068.		
	C385	PITZALIS, "Skin and joint disease in psoriatic arthritis: What is the link?" Br. J. Rheum. 37(5): 480-483 (1998).		
	C386	PITZALIS, et al., "Selective Migration of the Human Helper-Inducer Memory T Cell Subset: Confirmation by In Vivo Cellular Studies", European Journal of Immunology, vol. 21, pp. 369-376, 1991.		
	C387	PLATT, et al. "Transplantation of discordant xenografts: a review of progress", Immunol. Today 11(12):450-456 (1990)		
	C388	PODOLSKY, "Inflammatory Bowel Disease", The New England Journal of Medicine, vol. 325, No. 13, pp. 928-1014, 1991.		
	C389	POIKOLAINEN, et al., "Excess Mortality Related to Alcohol and Smoking Among Hospital-Treated Patients with Psoriasis", Arch Dermatol, vol. 135, pp. 1490-1493, 1999.		
	C390	POIZOT-MARTIN et al. (1991) "Are CD4 antibodies and peptide T new treatments for psoriasis" The Lancet 337:1477		
	C391	POLITO, et al., "Preliminary Evidence for Genetic Anticipation in Crohn's Disease", The Lancet, vol. 347, pp. 798-800, 1996.		
	C392	PRENS, et al., "T Lymphocytes in Psoriasis", Clinics in Dermatology, vol. 13, pp. 115-129, 1995.		
	C393	PRENTICE "Deaths Linked to Growth Hormone" The Times (London), April 6, 1991 (Cited for argument)		
	C394	PRINCE (1989) "Requirement For Both The CD3/T Cell Receptor Complex And The CD2/Lymphocyte Function-Associated Antigen-3 Adhesion System in Monocyte-Independent T Cell Activation By Oxidized Erythrocytes" Immunol. Investigations 18:1081-1093.		
	C395	PRINZ et al. (1991) "Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis" The Lancet 338:320-321.		
	C396	PRINZ, "Which T Cells Cause Psoriasis?", Clinical and Experimental Dermatology, vol. 24, pp. 291-295, 1999.		
	C397	QIN et al, "Induction of classical transplantation tolerance in the adult", J. Exp. Med. 169(3):779-794 (1989)		
	C398	QUEEN et al, "A humanized antibody that binds to the interleukin 2 receptor", PNAS 86:10029-10033 (1989)		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

25

of

33

**Complete if Known**

Application Number	10/588,323
Filing Date	February 7, 2005
First Named Inventor	MAGILAVY
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C399	RAMAKRISHNAN, S. and L. L. Houston, "Comparison of the Selective Cytotoxic Effects of Immunotoxins Containing Ricin A Chain or Pokeweed Antiviral Protein and Anti-Thy 1.1 Monoclonal Antibodies," Cancer Research, 44, pp. 201-208 (Jan. 1984).		
	C400	Rao, et al., "C-Terminal Modification Occurs in Tissue Culture Produced OKT3", Biopharm-The Technology & Business of Biopharmaceuticals, 1991, V4, N10, P38-43.		
	C401	RAU, et al., "Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy", J. Rheumatol. 25(8):1485-1492 (1998)		
	C402	RECNY et al. (1990) "Structural And Functional Characterization Of The CD2 Immuno adhesion Domain" J. Biol. Chem. 265(15):8542-8549.		
	C403	REETSMA, "Xenografts", Transplantation Proceedings 21(1):517-518 (1989)		
	C404	REFSUM, et al., "Fasting Plasma Homocysteine as a Sensitive Parameter of Antifolate Effect: A Study of Psoriasis Patients Receiving Low-Dose Methotrexate Treatment", Clinical Pharmacology Therapy, vol. 46, No. 5, pp. 510-520, 1989.		
	C405	REICHLIN, M., "Use of Glutaraldehyde as a Coupling Agent for Proteins and Peptides," In Methods in Enzymology, 70, edited by Van Vunakis et al., (Academic Press, New York, 1980) pp. 159-165 (1980).		
	C406	REICHMANN, et al., "Reshaping human antibodies for therapy", Nature 332:323-327 (1998)		
	C407	REILLY, et al., "Compartmental Analysis of the Pharmacokinetics of Radioiodinated Monoclonal Antibody B72.3 in Colon Cancer Patients", Nucl. Med. Biol, vol. 20, No. 1, pp. 57-64, 1993.		
	C408	REILLY, et al., "Problems of Delivery of Monoclonal Antibodies; Pharmaceutical and Pharmacokinetic Solutions", Clinical Pharmacokinetics, vol. 28, No. 2, pp. 126-142, 1995.		
	C409	REIMANN et al.; "In Vivo Administration of Lymphocyte-Specific Monoclonal Antibodies in Nonhuman Primates" (Transplantation--December 1989 pp. 906-912).		
	C410	RICHARDSON, N.E., et al., "Adhesion Domain of Human T11 (CD2) is Encoded by a Single Exon," Proc. Natl. Acad. Sci. (USA), 85, pp. 5176-5180 (1988).		
	C411	RIGGS et al. (1996), "The pharmacokinetic/pharmacodynamic (PK/PD) modeling of immunoglobulin fusion protein, LFA3TIP, using a non-linear saturable cell activity model," Pharmaceutical Research 13 (9 Supp.): s398 (Abstract)		
	C412	RINCON and Patarroyo (1989) "Effect Of Antibodies From The T Cell (CD2' Only) And The NK/Non-Lineage (New Panel Only) Sections On Adhesion Of Jurkat (T) Cell to Human Erythrocytes" Tissue Antigens 33:285.		
	C413	RIVERS, et al., "UVA Sunbeds: Tanning, Photoprotection, Acute Adverse Effects and Immunological Changes", British Journal of Dermatology, vol. 120, pp. 767-777, 1989.		
	C414	RODRIGUEZ, et al., "Optic Neuritis Posed a 40-Year Risk of 60% for Multiple Sclerosis", ACP Journal Club, vol. 122-123: 21, 1995.		
	C415	ROITT, Immunology, Gower Medical Pub. (1985) - Immunology textbook		
	C416	ROSE, "Risks of Cardiac Transplantation", Ann.Thoracic Surg. 47:645 (1989)		
	C417	ROSE, et al. "Immunosuppression in Cardiac Transplantation", Biblthca Cardiol. 43:1-9 (1988)		

Examiner Signature

/Phillip Gambel/

Date Considered

09/30/2008

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	26	of	33	Attorney Docket Number	253780

## OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C418	ROSE, et al. "Humoral immune responses after cardiac transplantation: Correlation with fatal rejection and graft atherosclerosis", Surgery 106(1):203-208 (1989)		
	C419	ROSE, et al., "Cardiac Xenotransplantation", Prog. Cardiovasc. Diseases 33(2):105-117 (1990)		
	C420	ROSE, et al., "Present Status of Human Cardiac Allografts and Prospects for Xenografts", Trans Am. Soc. Artif. Intern. Organs 34:19-23 (1988)		
	C421	RUDINGER, J. "Characteristics of the amino acids as components of a peptide hormone sequence" in Peptide Hormones, Parson, J. A. (Ed.), University Park Press, Baltimore, MD, pp. 1-7, 1976.		
	C422	SACHS, et al., "Immunology of Xenograft Rejection", Hum. Immunol. 28:245-251 (1990)		
	C423	SALMI, et al., "Dual Binding Capacity of Mucosal Immunoblasts to Mucosal and Synovial Endothelium in Humans: Dissection of the Molecular Mechanisms", Journal of Experimental Medicine, vol. 181, pp. 137-149, 1995.		
	C424	SALMI, et al., "Homing of Mucosal Leukocytes to Joints: Distinct Endothelial Ligands in Synovium Mediate Leukocyte-Subtype Specific Adhesion", Journal of Clinical Investigation, vol. 99, No. 9, pp. 2165-2172, 1997.		
	C425	SANCHEZ-MADRID, F. et al., "Three Distinct Antigens Associated with Human T-Lymphocyte-Mediated Cytolysis: LFA-1, LFA-2, and LFA-3," Proc. Natl. Acad. Sci, USA, 79, pp. 7489-7493 (Dec. 1982).		
	C426	SANDER, et al., "The Annual Cost of Psoriasis", Journal of the American Academy of Dermatology, vol. 28, No. 3, pp. 422-425, 1993.		
	C427	SANDERS et al. (1988) "T Cell Adhesion Receptors LFA-1 And CD2 And Their Ligands ICAM-1 And LFA-3" Analysis in Adhesion, Cell Mediated Lysis, And As Markers Of Cell Subsets in The T-Cell Receptor, A.R. Liss, Inc., pp. 269-279.		
	C428	SANDERS, et al., "Human Memory T Lymphocytes Express Increased Levels of Three Cell Adhesion Molecules (LFA-3, CD2, and LFA-1) and Three Other Molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma Production", The Journal of Immunology, vol. 140, No. 5, pp. 1401-1407, 1988		
	C429	SAVAGE et al. (1991), "Endothelial cell lymphocyte function-associated antigen-3 and an unidentified ligand act in concert to provide costimulation to human peripheral blood CD4.sup.+ T cells," Cellular Immunology 137(1): 150-163.		
	C430	SAYRE et al. (1987), "Molecular cloning and expression of T11 cDNAs reveal a receptor-like structure on human T lymphocytes" Chemical Abstracts 107(15): Abstract 128218x.		
	C431	SAYRE, et al. "Molecular cloning and expression of T11 cDNAs reveal a receptor-like structure on human T lymphocytes", PNAS 84:2941-2945 (1987)		
	C432	SCHNEIDER, et al., (Abstract) "A pilot study of the safety and efficacy of Alefacept in subject with active rheumatoid arthritis on methotrexate" European League Against Rheumatism (2003)		
	C433	SCHOPF (1986) "Stimulation of T Cells by Autologous Molecular Leukocytes and Epidermal Cells in Psoriasis" Arch. Dermatol. Res. 279:89-94.		
	C434	SCHOPF, "Interactions between epidermal cells and lymphocytes in psoriasis", Immunology Today 7:358 (1988)		

/Phillip Gambel/

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./



Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Examiner Name	Unassigned				
Attorney Docket Number	253780				
Sheet	27	of	33		

**OTHER - NON PATENT LITERATURE DOCUMENTS**


Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C435	SCHRAVEN, et al., "Alternations of CD2 Association with T Cell Receptor Signaling Molecules in 'CD2 Unresponsive' Human T Lymphocytes", European Journal of Immunology, vol. 23, pp. 119-123, 1993.		
	C436	SCHWARTZ, et al., "Identification of the TS2/18-Recognized Epitope on the CD2 Molecule as a Target for Suppression of T Cell Cytokine Synthesis", The Journal of Immunology, vol. 154, pp. 5813-5820, 1995.		
	C437	SCHWEIGHOFFER, et al. "Adhesions cascades: diversity through combinatorial strategies", Curr. Opin. Cell. Biol. 4(5):824-829 (1991)		
	C438	SEED, et al. (1987) "Molecular Cloning of the CD2 Antigen, The T-Cell Erythrocyte Receptor, By A Rapid immunoselection procedure" Proc. Natl. Acad. Sci. USA 84:3365-3369.		
	C439	SEED, B. "An LFA-3 cDNA Encodes a Phospholipid-Linked Membrane Protein Homologous to its Receptor CD2," Nature, 329, pp. 840-842 (1987).		
	C440	SEED, et al., "Molecular Cloning of the CD2 Antigen, the T-Cell Erythrocyte Receptor, By a Rapid Immunoselection Procedure," Proc. Natl. Acad. Sci. USA, 84, pp. 3365-3369 (May 1987).		
	C441	SELVARAJ et al. "Deficiency of Lymphocyte Function Associated Antigen 3 (LFA3) in Paroxysmal Nocturnal Hemoglobinuria," J. Exp. Med., 166, pp. 1011-1025 (1987).		
	C442	SELVARAJ et al. (1987) "The T Lymphocyte Glycoprotein CD2 (LFA-2/T11/E-Rosette Receptor) Binds The Cell Surface Ligand LFA-3" FASEB J. 46(3):447 Abstract 760.		
	C443	SELVARAJ, P. et al., "The T Lymphocyte Glycoprotein CD2 Binds the Cell Surface Ligand LFA-3," Nature, 326, pp. 400-403 (Mar. 1987).		
	C444	SEMNANI et al. (1994), "Costimulation by purified intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 induces distinct proliferation, cytokine and cell surface antigen profiles in human "naive" and "memory" CD4.sup.+ T cells," J. Exp. Med. 180:2125-2135.		
	C445	SEO, "Evaluation of Disease Activity in Patients with Moderately Active Ulcerative Colitis: Comparisons Between a New Activity Index and Truelove and Witts' Classification", The American Journal Of Gastroenterology, vol. 90, No. 10, pp. 1759-1763, 1995.		
	C446	SEWELL et al. (1986) "Molecular Cloning Of The Human T-Lymphocyte Surface CD2 (T11) Antigen" Proc. Natl. Acad. Sci. USA 83:8718-8722.		
	C447	SHAHIDULLAH, et al., "Etreinate Therapy for Psoriasis and Other Keratinizing Disorders: A 10-Year Retrospective Study in Singapore", International Journal of Dermatology, vol. 32, No. 9, pp. 686-689, 1993.		
	C448	SHANAHAN, "Pathogenesis of Ulcerative Colitis", The Lancet, vol. 342, pp. 407-411, 1993.		
	C449	SHAW et al. (1986) "Two Antigen-Independent Adhesion Pathways Used By Human Cytotoxic T-Cell Clones" Nature 323:262-264.		
	C450	SHAW, et al., "Cyclosporin A and Vitamin D Metabolism: Studies in Patients with Psoriasis and in Rats", Clinical Science, vol. 86, pp. 627-632, 1994.		
	C451	SHAW, S. and G. E. Ginther Luce, "The Lymphocyte Function-Associated Antigen (LFA)-1 and CD2/LFA-3 Pathways of Antigen-Independent Human T Cell Adhesion," J. Immunol., 139, pp. 1037-1045 (Aug. 15, 1987).		

Examiner Signature	/Phillip Gambel/	Date Considered	
--------------------	------------------	-----------------	--

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Examiner Name	Unassigned				
Sheet	28	of	33	Attorney Docket Number	253780


OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No**	
	C452	SHIMIZU, et al "Four Molecular Pathways of T Cell Adhesion to Endothelial Cells: roles of :FA-1, VCAM-1 and ELAM-1 and Changes in Pathway Hierarchy Under Different Activation Conditions", J. Cell. Biol. 113(5):1203-1212 (1991)			
	C453	SHORT, J. M., et al., ".lambda. ZAP: A Bacteriophage Expression Vector with In Vivo Excision Properties," Nucleic Acids Research, 16(15), pp. 7583-7600 (1988).			
	C454	SHUPAK, "Maintenance Therapy with Neoral.RTM.", International Journal of Dermatology, vol. 36, pp. 34-36, 1997.			
	C455	SIMON et al. (1991) "Adhesion molecules CD11a, CD18, and ICAM-2 on Human Epidermal Langerhans Cells Serve a Functional Role in the Activation of Alloreactive T Cells" Soc. Invest. Dermat. 96(1): 148-151.			
	C456	SINGER et al. (1990) "Thymocyte LFA-1 And Thymic Epithelial Cell ICAM-1 Molecules Mediate Binding Of Activated Human Thymocytes To Thymic Epithelial Cells" J. Immunol. 144(8):2931-2939.			
	C457	SINGER, K.H. et al. "The Role of Adhesion Molecules in Epithelial - T-Cell Interactions in Thymus and Skin", J. Invest. Dermatol. 94 (6) Supplement: 85S-90S.			
	C458	SINGH, et al., "Acute Immobilization Stress Triggers Skin Last Cell Degranulation via Corticotropin Releasing Hormone, Neurotensin, and Substance P: A Link to Neurogenic Skin Disorders", Brain Behavior, and Immunity, vol. 13, pp. 225-239, 1999.			
	C459	SMITH, et al. (1990) "Cellular Expression Of Lymphocyte Function Associated Antigens And The Intercellular Adhesion Molecule-1 In Normal Tissue" J. Clin. Path. 43 (11):893-900.			
	C460	SMITH, and Barker, "Cell Trafficking and Role of Adhesion Molecules in Psoriasis", Clinics in Dermatology, vol. 13, pp. 151-160, 1995.			
	C461	SOFER and Britton "Designing an Optimal Chromatographic Purification Scheme for Proteins" Bio/Techniques 1(4):198-203 (1983)			
	C462	SOMERVILLE, and Scott, "Neoral-New Cyclosporin For Old?", British Journal of Rheumatology, vol. 36, pp. 1113-1115, 1997.			
	C463	SOUTHERN, E. M. "Detection of Specific Sequences Among DNA Fragments Separated by Gel Electrophoresis", J. Mol. Biol., 98, 503-517 (1975).			
	C464	SPADARO, et al., "Comparison of cyclosporine A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study", Clin. Exp. Rheum. 13:589-593 (1995)			
	C465	SPRINGER "Adhesion Receptors Of The Immune System" Nature 346:425-434.			
	C466	SPRINGER (1987) "The Lymphocyte Function-Associated LFA-1, CD2, And LFA-3 Molecules: Cell Adhesion Receptors Of The Immune System" Ann. Rev. Immunol. 5:223-252.			
	C467	SPULS et al., "A Systematic Review of Five Systematic Treatments for Severe Psoriasis", British Journal of Dermatology, vol. 137, pp. 943-949, 1997.			
	C468	SRINIVASACHAR, K. and D. M. Neville, Jr., "New Protein Cross-Linked Reagents That Are Cleaved by Mild Acid," Biochemistry, 28(4), pp. 2501-2509 (1989).			
	C469	STAUNTON et al. (1989) "Molecular characterization of ICAM-1 and ICAM-2; Alternate Ligands for LFA-1" Tissue Antigens 33:287 (Abstract)			
	C470	Stedman's Medical Dictionary, (1976) The Williams & Wilkins Company, Baltimore, MD, p. 810.			

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	29	of	33	Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C471	STERN, "Narrowband UV-B and Psoriasis", Arch Dermatol, vol. 133, pp. 1587-1588, 1997.		
	C472	STERN, "Psoriasis", The Lancet, vol. 350, pp. 349-353, 1997.		
	C473	STERN, "Utilization of Outpatient Care for Psoriasis", Journal of the American Academy of Dermatology, vol. 35, No. 4, pp. 543-549, 1996.		
	C474	STERN, et al., "Malignant Melanoma in Patients Treated for Psoriasis with Methoxsalen (Psoralen) and Ultraviolet A Radiation (PUVA)", The New England Journal of Medicine, vol. 336, No. 15, pp. 1041-1045, 1997.		
	C475	STERN, et al., "The Safety of Etretinate as Long-Term Therapy for Psoriasis: Results of the Etretinate Follow-Up Study", Journal of the American Academy of Dermatology, vol. 33, No. 1, pp. 44-52, 1995.		
	C476	STORKUS, and Dawson, "A Target Structures Involved in Natural Killing (NK): Characteristics, Distribution, and Candidate Molecules", Immunology, vol. 10, No. 5, 393-416, 1991.		
	C477	STRAND, "The Future Use of Biologic Therapies in Combination for the Treatment of Rheumatoid Arthritis", J. Rheumatol. 23 (suppl. 44):91-96 (1996)		
	C478	SULTAN, et al., "Blockade of CD2-LFA-3 Interactions Protects Human Skin Allografts in Immunodeficient Mouse/Human Chimeras", Nature Biotechnology, vol. 15, pp. 759-762, 1997.		
	C479	SURANJI et al. (1991) "Lymphocyte Adhesion Molecules in T Cell-Mediated Lysis of Human Kidney Cells" Kidney International 39:312-319.		
	C480	SUTHERLAND, et al., "Standards for Trials of Therapy in Inflammatory Bowel Disease", Inflammatory Bowel Diseases, vol. 3, No. 4, pp. 277-283, 1997.		
	C481	TADINI (1989) "Adhesion Molecules Expression in Psoriasis" J. Invest. Dermatol. 93(2):309A (Abstract).		
	C482	TALWAR, et al., "Sequential Clinico-Histological Studies in Psoriasis Following Methotrexate Therapy", Ind J Dermatol Venereol Leprol, vol. 61, pp. 284-287, 1995.		
	C483	TAND and Udey (1991) "Inhibition of Epidermal Langerhans Cell Function by Low Dose of Ultraviolet B Radiation" J. Immunol. 146(10):3347-3355.		
	C484	Task Force of the Working Group on Arrhythmias of the European Society of Cardiology, "The Early Termination of Clinical Trials: Causes, Consequences, and Control", European Heart Journal, vol. 15, pp. 721-738, 1994.		
	C485	The Merck Manual of Diagnosis and Therapy Sixteenth Edition Edited by Berkow et al., Merck Research Laboratories, Rahway NJ 1992, pp. 2435-2445.*		
	C486	THOMAS, et al., "Transdermal Nicotine as Maintenance Therapy for Ulcerative Colitis", The New England Journal of Medicine, vol. 332, No. 15, pp. 988-992, 1995.		
	C487	THOMAS, et al., "Purification of Membrane Proteins" in Methods in Enzymology, Deutscher, M. ed., (Academic Press, San Diego) 182: 499 (1990) (cited for argument)		
	C488	TICHO, et al., "Reduced T cell monitoring in psoriasis patients receiving alefacept: results of clinical studies and mathematical modeling", J. Inves. Derm. 124(4): A40 (2005) (Abstract)		
	C489	TRAUNECKER et al., "A novel approach for preparing anti-T cell receptor constant region antibodies", 1986, Eur. J. Immunol., vol. 16:851-854.		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./**

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Examiner Name	Unassigned				
Attorney Docket Number	253780				
Sheet	30	of	33		

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C490	TRAUNECKER et al., "Soluble CD4 molecules neutralize human immunodeficiency virus type 1", 1988, Nature, vol. 331:84-86.		
	C491	TRAUPE, "The Puzzling Genetics of Psoriasis", Clinics in Dermatology, vol. 13, pp. 99-103, 1995.		
	C492	TREMBATH, et al., "Identification of a Major Susceptibility Locus on Chromosome 6p and Evidence for Further Disease Loci Revealed by a Two Stage Genome-Wide Search in Psoriasis", Human Molecular Genetics, vol. 6, No. 5, pp. 813-820, 1997.		
	C493	UCHIO, et al., "Suppression of Experimental Uveitis With Monoclonal Antibodies to ICAM-1 and LFA-1", Invest. Ophthalmol. Vis. Sci. 35(5):2626-2631 (1994)		
	C494	ULLMAN et al. (1990) "Transmission of Signals from T Lymphocyte Antigen Receptor to the Genes Responsible for Cell Proliferation and Immune Function: The Missing Link" Ann. Rev. Immunol. 8:421-452.		
	C495	URLAUB, and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity", Proc Natl Acad Sci, vol. 77, No. 7, pp. 4216-4220, 1980.		
	C496	URLAUB, et al., "Effect of Gamma Rays at the Dihydrofolate Reductase Locus: Deletions and Inversions", Somatic Cell and Molecular Genetics, vol. 12, No. 6, pp. 555-566, 1986.		
	C497	VALDIMARSSON et al. (1986) "Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes" Immunol. Today 7:256-259.		
	C498	VALDIMARSSON, et al., "Psoriasis: A T-Cell-Mediated Autoimmune Disease Induced by Streptococcal Superantigens?", Immunology Today, vol. 16, No. 3, pp. 145-149, 1995.		
	C499	VAN DE KERKHOF, "An Update on Vitamin D3 Analogues in the Treatment of Psoriasis", Skin Pharmacology and Applied Skin Physiology, vol. 11, pp. 2-10, 1998.		
	C500	VAN DE KERKHOF, "Reduction of Epidermal Abnormalities and Inflammatory Changes in Psoriatic Plaques During Treatment with Vitamin D3 Analogs", Journal of Investigative Dermatology Symposium Proceedings, vol. 1, pp. 78-81, 1996.		
	C501	VAN DE KERKHOF, "Review: The Management of Psoriasis", Netherlands Journal of Medicine, vol. 52, pp. 40-45, 1998.		
	C502	VAN DE KERKHOF, "The Psoriasis Area and Severity Index and Alternative Approaches for the Assessment of Severity: Persisting Areas of Confusion", British Journal of Dermatology, vol. 137, pp. 661-662, 1997.		
	C503	VAND DE KERKHOF, et al., "Evaluation of Topical Drug Treatment in Psoriasis", Dermatology, vol. 197, pp. 31-36, 1998.		
	C504	VAN DE KERKHOF, et al., "The Effect of Addition of Calcipotriol Ointment (50 .mu.g/g) to Acitretin Therapy in Psoriasis", British Journal of Dermatology, vol. 138, pp. 84-89, 1998.		
	C505	VAN DER MERVE, et al., "Human Cell-Adhesion Molecule CD2 Binds CD58 (LFA-3) with a Very Low Affinity and an Extremely Fast Dissociation Rate but does not Bind CD48 or CD59", Biochemistry, vol. 33, pp. 10149-10160, 1994.		
	C506	VAN DER RHEE, et al., "Combined Treatment of Psoriasis with a New Aromatic Retinoid (Tigason) in Low Dosage Orally and Triamcinolone Acetonide Cream Topically: A Double-Blind Trial", British Journal of Dermatology, vol. 102, pp. 203-211, 1980.		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>		
				Application Number	10/588,323	
				Filing Date	February 7, 2005	
				First Named Inventor	MAGILAVY	
				Group Art Unit	1644	
Examiner Name	Unassigned					
Attorney Docket Number	253780					
Sheet	31	of	33			

## OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C507	VAN KOOYK, et al., "Enhancement of LFA-1-Mediated Cell Adhesion by Triggering through CD2 or CD3 on T Lymphocytes", Nature, vol. 342, pp. 811-813, 1989.		
	C508	VAN NORT, et al., "Cell Biology of Autoimmune Diseases", in International Review of Cytology: A Survey of Cell Biology, Jeon, K. ed. (Academic Press, San Diego, 1998), pp127-207		
	C509	VAN ONSELEN, "Psoriasis in General Practice", Nursing Standard, vol. 12, No. 30, pp. 32-33, 1998.		
	C510	VAN SEVENTER et al. (1989) "The Three LFA-3 Specific Monoclonal Antibodies in the Non-Lineage panel of Workshop Monoclonal Antibodies All Inhibit T-Cell Rosetting" Tissue Antigens 33:298 (Abstract).		
	C511	VAN SEVENTER, et al. "Roles of multiple accessory molecules in T-cell activation", Curr. Opin. Immunol. 3(3):294-303 (1991)		
	C512	VERHOEVEN, et al., "Combination Therapy in Rheumatoid Arthritis: Updated systematic review", Br. J. Rheum. 37:612-619(1998)		
	C513	VERSTUYF, et al., "Recent Developments in the Use of Vitamin D Analogues", Expert Opin Investig Drugs, vol. 9, No. 3, pp. 397-403, 1998.		
	C514	VIRELLA et al. (1988) "The Interaction of CD2 With Its LFA-3 Ligand Expressed By Autologous Erythrocytes Results in Enhancement of B Cell Responses" Cell. Immunol. 116:308-319.		
	C515	VOLLGER et al. (1987) "Thymocyte Binding To Human Tymic Epithelial Cells is Inhibited By Monoclonal Antibodies To CD-2 And LFA-3 Antigens" J. Immunol. 138(2):358-363.		
	C516	WAHL, "The Impact of Psoriasis on Psychosocial Life Domains: A Review", Scandinavian Journal of Caring Science, vol. 11, pp. 243-249, 1997.		
	C517	WAHL, et al., "Sulfasalazine: A Potent and Specific Inhibitor of Nuclear Factor Kappa B", Journal of Clinical Investigation, vol. 101, No. 5, pp. 1163-1174, 1998.		
	C518	WALDMAN (1991) "Monoclonal Antibodies in Diagnosis and Therapy" Science 252:1657-1662.		
	C519	WALLNER et al (1987) "Primary Structure of Lymphocyte Function-Associated Antigen 3 (LFA-3)--The Ligand of the Lymphocyte CD2 Glycoprotein" J. Exp. Med. 166(4):923-931.		
	C520	WALLNER, et al., "Cloning and Expression of Human Lipocortin, a Phospholipase A2 Inhibitor with Potential Anti-Inflammatory Activity", Nature, 320(6), 77-81 (1986).		
	C521	WALTERS, et al., "Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris", J.Acad. Dermatol. 40(6) 893-900		
	C522	WANG, et al., "Structure of a Heterophilic Adhesion Complex between the Human CD2 and CD58 (LFA-3) Counterreceptors", Cell, vol. 97, pp. 971-803, 1999.		
	C523	WANG, X. et al., "A Vector That Expresses Secreted Proteins on the Cell Surface," DNA, 8(10), pp. 753-758 (Dec. 1989).		
	C524	WANQUINQ, et al., "Clinical Study of Cyclosporin A for Psoriasis in China", Annals of Dermatology, vol. 7, No. 4, pp. 313-317, 1995.		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/588,323
				Filing Date	February 7, 2005
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
Sheet	32	of	33	Examiner Name	Unassigned
				Attorney Docket Number	253780

## OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C525	WATANABE, et al., "Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques", Nature 337:267(1989) (cited for argument)		
	C526	WEBB et al. (1990) "LFA-3, CD44, And CD45: Physiologic Triggers Of Human Monocyte TNF And IL-1 Release" Science 249:1295-1297.		
	C527	WEINBLATT, "Efficacy of Methotrexate in Rheumatoid Arthritis" Br. J. Rheum. 34(S2):43-48 (1995)		
	C528	WEINBLATT, et al., "Methotrexate for Chronic Diseases in Adults", The New England Journal of Medicine, vol. 332, No. 5, pp. 330-331, 1995.		
	C529	WEINBLATT, et al., "Efficacy of Methotrexate in Rheumatoid Arthritis", Br. J. Rheum. 34(Supp 2):43-48 (1995)		
	C530	WEINER, et al., "Phase I Evaluation of an Anti-Breast Carcinoma Monoclonal Antibody 260F9-Recombinant Ricin A Chain Immunoconjugate", Cancer Research, vol. 49, pp. 4062-4067, 1989.		
	C531	WEINSTEIN, "Psoriasis Therapy After Remission: The Next Step", International Journal of Dermatology, vol. 36(Suppl 1), pp. 37-40, 1997.		
	C532	WEINSTEIN, "Tazarotene Gel: Efficacy and Safety in Plaque Psoriasis", Journal of the American Academy of Dermatology, vol. 37, No. 2, pp. S33-S38, 1997.		
	C533	WEINSTEIN, et al., "Tazarotene Gel, a New Retinoid, for Topical Therapy of Psoriasis: Vehicle-Controlled Study of Safety, Efficacy, and Duration of Therapeutic Effect", Journal of the American Academy of Dermatology, vol. 37, No. 1, pp. 85-92, 1997.		
	C534	WEISS, and Ashwell, "The Asialoglycoprotein Receptor: Properties and Modulation by Ligand", Baumann, P., et al. (ED.). Progress in Clinical and Biological Research, vol. 300.		
	C535	WENDLING, et al. "Therapeutic Use of Monoclonal Anti-CD4 Antibody in Rheumatoid Arthritis", J. Rheum. 18(3): 325-7 (1991) ) (abstract only)		
	C536	WEYAND, et al. "Immunosuppression by Anti-CD4 Treatments In Vivo", Transplantation 47(6):1039-1042 (1989)		
	C537	WHITCUP, et al., "Monoclonal Antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) Inhibit Experimental Autoimmune Uveitis", Clin. Immunol Immunopathol 67(2):143-150 (1993)		
	C538	WHITMORE, and Morison, "Melanoma after PUVA Therapy for Psoriasis", The New England Journal of Medicine, vol. 337, No. 7, pp. 502, 1997.		
	C539	WILLKENS, et al., "Randomized, Double-Blind, Placebo Controlled Trial of Low-Dose Pulse Methotrexate in Psoriatic Arthritis", Arthritis and Rheumatism, vol. 27, No. 4, pp. 376-381, 1984.		
	C540	WINTER and Harris (1993) "Humanized antibodies" TiPS 14(5):139-142.		
	C541	WOLSKA, et al., "Etretnate in Severe Psoriasis: Results of Double-Blind Study and Maintenance Therapy in Pustular Psoriasis", Journal of the American Academy of Dermatology, vol. 9, No. 6, pp. 883-887, 1983.		
	C542	WONG et al., "Identification of a Partial cDNA Clone for the Human Receptor for Complement Fragments C3b/C4b," Proc. Natl. Acad. Sci. U.S.A., 82, 7711-7715 (1985).		

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

33

of

33

**Complete if Known**

Application Number	10/588,323
Filing Date	February 7, 2005
First Named Inventor	MAGILAVY
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	253780

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C543	WONG, et al., "Mechanisms of action of cyclosporine A in the treatment of psoriasis", Immunol. Today 14(2):69-74 (1993).		
	C544	WOOD, W. I. (1987) "Gene Cloning Based on Long Oligoneucleotide Probes", Meth. Entymol. 152:443-47.		
	C545	WRIGHT, et al., "Human Low-Dosage Parenteral Methotrexate Therapy: A Controlled Toxicity Study", Arch Derm, vol. 93, pp. 731-736, 1966.		
	C546	Written Opinion PCT/US02/02314		
	C547	YAMASHITA, et al., "A multimeric form of soluble recombinant sheep LFA-3 (CD-58) inhibits human T-cell proliferation" Immunol. 92(1):39-44 (1997)		
	C548	YEH, et al., "Recombinant Soluble Human Complement Receptor Type 1 Inhibits Inflammation in the Reversed Passive Arthus Reaction in Rats", J. Immunol. 146(1):250 (1991) (cited for argument		
	C549	YOCUM, et al., "Clinical and immunological effects of a Primatized Anti-CD4 Monoclonal Antibody in Active Rheumatoid Arthritis: Results of a Phase I, Single Dose, Dose Escalating Trial", Journal of Rheumatology, vol. 25, pp. 1257-1262, 1998.		
	C550	YONG and Khwaja (1990) "Leukocyte Cellular Adhesion Molecules" Blood Reviews 4(4):211-225.		
	C551	YOUNG, et al., "A Prospective study of Renal Structure and Function in Psoriasis Patients with Cyclosporin", Kidney International, vol. 46, pp. 1216-1222, 1994.		
	C552	ZACHARIAE, "Alcohol Interaction with Drugs and its Effects on the Treatment of Skin Diseases", Clinics in Dermatology, vol. 17, pp. 443-445, 1999.		
	C553	ZETTLMEISSL, et al., "Expression and Characterization of Human CD4: Immunoglobulin Fusion Proteins", DNA & Cell Biol. 9(5):347-353 (1990)		
	C554	ZHENG et al. (1990) "Expression Of Intercellular Adhesion Molecule-1 And Lymphocyte Function-Associated Antigen-3 On Human Thyroid Epithelial Cells In Graves' And Hashimoto's Diseases" J. Autoimmunity 3:727-736.		
	C555	Translation of Examiner's report for Czech Patent Application No. PV 2001-725		

Examiner Signature

/Phillip Gambel/

Date Considered

09/30/2008

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./